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Abstract

CANNABINOID MODULATION OF CHEMOTAXIS OF MACROPHAGES AND
MACROPHAGE-LIKE CELLS
By Erinn S. Raborn, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2007
Major Director: Guy A. Cabral, Ph.D.
Professor, Department of Microbiology and Immunology

Exogenous and endogenous cannabinoids have been reported to modulate
functional activities of macrophages. It is recognized that macrophages express primarily
the CB2 cannabinoid receptor, but recent studies indicate that its expression is differential
in relation to activation state with maximal levels occurring when cells are in
“responsive” and “primed” states. The functional activities of macrophages when in
these states of activation are the most susceptible to the action of cannabinoids, at least in
terms of a functional linkage to the CB2. To assess the effect of cannabinoid treatment on
macrophage chemotaxis and test the hypothesis that cannabinoids inhibit the chemotactic
response of macrophages and microglia to endogenous and exogenous, pathogen-derived
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stimuli, primary murine peritoneal macrophages and neonatal rat microglia were used.
Chemotaxis assays and scanning electron microscopy studies demonstrated that
cannabinoids inhibit chemotaxis, a signature activity attributed to “responsive”
macrophage-like cells, to the endogenous chemokine RANTES (Regulated upon
Activation Normal T-cell Expressed and Secreted) and to Acanthamoeba conditioned
medium containing secreted proteases. The partial agonist delta-9-tetrahydrocannabinol
(THC), administered in vitro, inhibited the chemotactic response of peritoneal
macrophages to the chemokine RANTES and to Acanthamoeba conditioned medium. In
vivo treatment with THC also resulted in inhibition of the in vitro chemotactic response
of murine peritoneal macrophages to RANTES and amoebic conditioned medium.
Pharmacological studies employing cannabinoid receptor agonists and antagonists
demonstrated the involvement of CB2 in cannabinoid-mediated inhibition of peritoneal
macrophage chemotaxis to RANTES and Acanthamoeba conditioned medium, implying
that signaling through cannabinoid receptors may desensitize chemokine receptors.
Treatment with cannabinoids had no apparent effect on chemokine receptor mRNA
levels, but did enhance CCR5 protein phosphorylation. Macrophage migration to
Acanthamoeba conditioned medium may involve activation and signaling through
protease activated receptors (PARs), as pathogen-derived proteases have been shown to
activate PARs and initiate cellular migration; however, further studies are required to
demonstrate PAR activation by amoebic conditioned medium and to assess the effects of
cannabinoids on PAR signaling.

xiii

Acanthamoeba are opportunistic pathogens that cause Granulomatis amoebic
encephalitis, an infection of the CNS that is often fatal. THC treatment has been shown
to increase mortality to Acanthamoeba infections and is characterized by an absence of
granuloma formation. We hypothesize that inhibitory effect of THC on macrophage
migration may be a key factor in cannabinoid-mediated immunosuppression. To assess
the effect of cannabinoids on microglial migration to Acanthamoeba conditioned
medium, chemotaxis assays were performed using primary rat microglia treated with
cannabinoids. These studies demonstrated that cannabinoids inhibit microglial
chemotaxis to amoebic conditioned medium.
Furthermore, the studies demonstrate that cannabinoids, acting through
cannabinoid receptors, may cross-talk with a diverse array G-protein coupled receptors so
as to modulate responsiveness of macrophage and macrophage-like cells.
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Introduction
Cannabis is one of the oldest and most widely used drugs in human history, with
references to its use in ancient Chinese civilization dating to 2737 BC (Li, 1974).
Medicinal use of cannabis continued freely in Western countries throughout the 1800s
and into the mid-1900s. However, in 1942, cannabis was withdrawn from the United
States Pharmacopoeia (USP), a compendium published annually by the United States
Pharmacopoeia Convention providing standardization of therapeutic drugs. Great Britain
and many other European countries prohibited cannabis use in 1971, by adopting policies
proposed by the United Nations-led Convention on Psychotropic Substantces (Ben Amar,
2006).
The marijuana plant (Cannabis sativa) contains over 450 known chemicals
including more than 60 pharmacologically active compounds called cannabinoids.
Cannabinoids have been shown to elicit a variety of physiological effects including
impairments of short-term memory, attention span, and motor function, in addition to
numerous psychological effects including paranoia, altered perception, and hallucinations
(Martin, 1986). Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive
component in marijuana. This exogenous cannabinoid exerts a variety of modulatory
effects on the immune system, the majority of which have been reported to be
immunosuppressive (Klein et al., 1998; Cabral and Dove Pettit, 1998; Cabral and Staab,
2005). In this capacity, THC affects a diverse array of immune cell types, including B
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lymphocytes (Klein et al., 1985), Natural Killer cells (Specter et al., 1986), T
lymphocytes (Zimmerman et al., 1977), macrophages (Raz and Goldman, 1976;
Friedman et al., 1986) and macrophage-like cells (Puffenbarger et al., 2000).
Cannabinoid effects on cellular systems can occur by both receptor-mediated and nonreceptor-mediated modes (Makriyannis et al., 1990; Felder et al., 1992; Berdyshev et al.
2001; Price et al., 2004). In terms of receptor-mediated action, two cannabinoid
receptors have been identified and linked to THC effects on immune function. The first
of these, CB1, is found at highest levels in the central nervous system (CNS) with
expression in the hippocampus, basal ganglia, cerebral cortex, amygdala and cerebellum
correlating with observed neurological effects of cannabinoids (Matsuda et al., 1990;
Galiégue et al., 1995; Herkenham et al., 1991). CB1 is present in the testis (Galiégue et
al., 1995) and also at low levels in various immune cells (Galiégue et al., 1995; Daaka et
al., 1996; Waksman et al., 1999). The second receptor, CB2, is found primarily in
immune cells (Munro et al., 1993; Galiégue et al., 1995) and appears to play a major role
in immune modulation (Klein et al., 1998; Cabral and Dove Pettit, 1998; Cabral and
Staab, 2005). Both cannabinoid receptors are members of a large receptor superfamily
known as G-protein coupled receptors (GPCRs), and characteristically have seven
transmembrane domains and initiate cellular signal transduction through coupling with G
proteins. Both CB1 and CB2 receptors are coupled to Gi/o proteins. Cannabinoid receptor
signaling through these G proteins inhibits cyclic adenosine 3’,5’-monophosphate
(cAMP) and subsequent activation of protein kinase A (PKA) and activates mitogen
activated protein kinase (MAP kinase)(Berdyshev, 2000). Cannabinoid receptor

3

signaling involves numerous second messengers and converges with multiple signal
transduction pathways that are critical in the immune response.
Of the various immune cell populations affected by THC and other cannabinoids,
macrophages and macrophage-like cells appear to be a major target (Munro et al., 1993;
Cabral et al., 1995; Waksman et al., 1999; Puffenbarger et al., 2000). Ultrastructural
abnormalities have been observed in alveolar macrophages of humans who have been
heavy users of marijuana (Mann et al., 1971) and in peritoneal macrophages of mice
exposed in vitro to various concentrations of THC (Raz and Goldman, 1976). Various
functional defects of alveolar and peritoneal macrophages from humans, rats or mice
following in vivo or in vitro exposure to marijuana or THC also have been reported.
These alterations have included decreases in cell motility, ability to spread in vitro,
release of β-glucuronidase, phagocytosis of yeast particles, and inactivation of
Staphylococcus aureus and S. albus (Huber et al., 1975; Chari-Briton, 1976; McCarthy et
al., 1976; Drath et al., 1979; Huber et al., 1978; Lopez-Cepero et al., 1986; Specter et al.,
1991; Tang et al., 1992). In addition, THC has been reported to affect macrophage
processing of soluble protein antigens (McCoy et al., 1995; 1999). THC and other
cannabinoids also have been shown to modulate the production of cytokine and
chemokines by peripheral macrophages as well as microglia, the resident macrophages
within the CNS (Klein et al., 2000; McCoy et al., 1995; Puffenbarger et al., 2000;
Srivastava et al., 1998; Waksman et al., 1999; Zheng et al., 1992).
Macrophages play a critical role in both innate immunity as well as cell-mediated
immunity. The primary functions of these cells are to navigate to sites of tissue damage
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or infection, phagocytose cellular debris or pathogens, and stimulate lymphocytes and
other immune cells to respond to the pathogen. Integral to this process is the recruitment
of macrophages, which occurs early in the inflammatory process and is mediated by
specific chemical stimuli. This migratory activity is distinctive from that of stimulusindependent random cellular motion (Lauffenburger and Horwitz, 1996; Mitchison and
Cramer, 1996). The two major modes of stimulus-dependent cellular motility are
chemokinesis and chemotaxis. Chemokinesis is a process whereby cells exhibit random,
non-directional motion that is dependent on a chemical stimulant (Becker, 1977; Keller et
al., 1978). On the other hand, chemotaxis is a process in which cell motility is directed
toward a concentration gradient of a chemical stimulant (Harris, 1953, 1954; Jin and
Hereld, 2006; Kehrl, 2006). In this chemotactic process, macrophage interaction with
chemoattractants not only initiates rapid and directed movement, but also is associated
with a complex array of cellular events that includes changes in ion fluxes, alterations in
integrin expression and avidity, production of superoxide anions, and secretion of
lysosomal enzymes (Murdoch and Finn, 2000). “Classical” chemoattractants include
bacterial-derived N-formyl peptides, the complement fragment peptides C5a and C3a,
and lipids such as leukotriene B4 and platelet-activating factor (Schiffman et al., 1975;
Goldman and Goetzl, 1982; Hanahan, 1986; Gerard and Gerard, 1994). Chemokines
represent a second group of chemoattractants. These secreted cytokines range from 8- to
17-kD molecular mass and are selective for leukocytes in vitro, in addition to eliciting the
accumulation of inflammatory cells in vivo (Baggiolini et al., 1994, 1997; Kim, 2004; Le
et al., 2004). Chemokines have been categorized into four groups on the basis of their N-
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terminal cysteine motifs - CXC (α-chemokines), CC (β-chemokines), CX3X (δchemokines), and C (γ-chemokines) (Murphy, 2000) (Table 1). As in the case for
cannabinoid receptors, the specific effects of chemokines on target cells are mediated by
G protein-coupled receptors (Murdoch and Finn, 2000; Charo and Ransohoff, 2006).
Ligation of chemokines with their cognate receptors initiates a series of signal
transductional events that results in regulation of leukocyte trafficking in inflammation,
tissue injury, tumor development and host response to infection (Charo and Ransohoff,
2006). Correlative to chemokine nomenclature, four families of chemokine receptors
have been defined based on the chemokines they bind (CC, CXC, CX3C, or C), followed
by R for receptor and a number indicating the order in which they were discovered
(Murphy, 2002) (Table 2).
G protein coupled receptors have been reported to cross-talk through a process
known as heterologous desensitization. Chemokine receptor activity has been shown to
be inhibited by the activation of numerous classes of GPCRs including opioid receptors
and adenosine receptors (Zhang and Oppenheim, 2005). Activation of one type of GPCR
can result in the phosphorylation of cytosolic C-terminal residues of other GPCRs by G
protein coupled receptor kinases (GRKs) or other second messenger kinases.
Phosphorylated receptors are unable to couple to G proteins; therefore, subsequent ligand
binding does not initiate signal transduction. GPCR crosstalk may play an important role
in the integration of diverse systems and the overall maintenance of immune homeostasis.
Alternately, dysregulation of this crosstalk through the addition of exogenous compounds
may constitute a significant element of drug-related immunosuppression. For example,
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opioid desensitization of chemokine receptors has been directly implicated in
immunosuppression consequent of opioid use (Rogers et al., 2000). Macrophages also
play an important role in pathogen recognition and clearance, and appear to be the
primary effector cell in the immune response against Acanthamoeba infection (MarcianoCabral et al., 2003). The free-living amoebae of the genus Acanthamoeba are
opportunistic pathogens with ubiquitous distribution. These microorganisms have been
isolated world-wide from varied environments including soil, sewage, hospitals,
seawater, drinking water treatment plants, and contact lenses (Marciano-Cabral et al.,
2003). Acanthamoeba spp. are also the causative agents of granulomatous amebic
encephalitis (GAE), amebic keratitis and cutaneous amebiasis in humans.
Granulomatous amebic encephalitis is a progressive infection of the CNS that is
often fatal, especially in the immunocompromised. Acanthamoeba access to the CNS
may occur through the olfactory neuroepithelium following inhalation through the nasal
passages or via hematogenous spread from a cutaneous lesion (Martinez et al., 1985).
Pathological findings from fatal cases of GAE reveal inflammation and severe
hemorrhagic necrosis. The latter is presumably caused by a combination of direct
destruction of brain tissue by feeding amoeba, secretion of lytic factors by amoeba, and
prolonged induction of inflammatory cytokines such as tumor necrosis factor-alpha
(TNF-α) and interleukin-1 (IL-1) (Marciano-Cabral et al., 2000).
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Table 1 – CC Chemokine Nomeclature
Symbol
CCL1
CCL2
CCL3
CCL4
CCL5
CCL6
CCL7
CCL8
CCL9
CCL10
CCL11
CCL12
CCL13
CCL14
CCL15
CCL16
CCL17
CCL18
CCL19
CCL20
CCL21
CCL22
CCL23
CCL24
CCL25
CCL26
CCL27
CCL28

Alternate Name(s)
TCA3, I-309
MCP-1 (monocyte chemotactant protein-1)
MIP-1α (macrophage inflammatory protein1-alpha)
MIP-1β (macrophage inflammatory protein1-beta)
RANTES (Regulated upon activation normal T cell expressed and
secreted)
C10, MRP-1 (MIP-related protein-1)
MCP-3 (monocyte chemotactant protein-3)
MCP-2 (monocyte chemotactant protein-2)
MIP-1γ ( macrophage inflammatory protein1-gamma), MRP-2 (MIPrelated protein-2)
now CCL9
eotaxin
MCP-5 (monocyte chemotactant protein-5)
MCP-4 (monocyte chemotactant protein-4)
HCC1 (human CC chemokine 1)
MIP-5 (macrophage inflammatory protein-5), HCC-2
LEC (liver expressing chemokine), Mnt-1 (monotactin-1)
TARC (thymus and activation related chemokine)
MIP-4 (macrophage inflammatory protein-4), PARC (pulmonary and
activation regulated chemokine)
MIP-3β (macrophage inflammatory protein3-beta)
MIP-3α (macrophage inflammatory protein3-alpha), LARC (liver
activation regulated chemokine
6Ckine, SLC (secondary lymyphoid-tissue chemokine)
MDC (macrophage derived chemokine)
MIP-3 (macrophage inflammatory protein-3), MPIF-1 (myeloid progenitor
inhibitory factor-1)
eotaxin-2, MPIF-2 (myeloid progenitor inhibitory factor-2)
TECK
MIP-4α (macrophage inflammatory protein4-alpha), eotaxin-3
CTAK (cutaneous T-cell attracting chemokine)
MEK (mucosal-associated epithelial chemokine)
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Table 2- CC Chemokines and Chemokine Receptors
Receptor

Ligand(s)

Primary Functions

CCR1

CCL3, CCL5, CCL7,
CCL8, CCL13-16, CCL23

T cell and monocyte
migration, inflammation

CCR2

CCL2, CCL8, CCL7,
CCL13

T cell and monocyte
migration, inflammation

CCR3

CCL5, CCL7, CCL8,
CCL11, CCL13, CCL15,
CCL24, CCL26

Eosinophil, basophil, T cell
migration

CCR4

CCL17, CCL22

T cell and monocyte
Migration

CCR5

CCL3, CCL4, CCL5,
CCL8, CCL14

T cell and monocyte
migration

CCR6

CCL20

Dendritic cell migration

CCR7

CCL19, CCL21

T cell and dendritic cell
migration

CCR8

CCL1, CCL4, CCL14

T cell trafficking

CCR9

CCL25

T cell trafficking

CCR10

CCL26-28

T cell trafficking

Adapted from Murphy et al., 2002.
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THC has been shown to increase host susceptibility to a wide variety of
pathogenic bacteria, protozoa, and viruses (reviewed in Cabral and Dove Pettit, 1998).
Experiments using an in vivo animal model of Acanthamoeba infections performed by
Marciano-Cabral et al. (2001) demonstrated that (B6C3)F1 mice injected with THC and
exposed to Acanthamoeba intranasally had a higher incidence of mortality compared with
vehicle treated animals. While macrophages are thought to be the primary immune cell
involved in host response to Acanthamoeba infection, the specific effect of THC on
macrophage function has not been fully defined. Histopathological analysis of brain
slices from mice and humans with GAE show the formation of immune cell granulomas,
containing macrophages and neutrophils, surrounding the amoebae (Marciano-Cabral et
al., 2003; Cabral et al., in press 2007). These granulomas are conspicuously absent in
THC-induced immunosuppression, indicating that THC may impair the macrophage
migratory response.
The goal of the present study was divided into three main objectives. Initially, we
sought to assess the effect of THC on the chemotactic response of murine peritoneal
macrophages to RANTES/CCL5 (Regulated upon Activation Normal T cell Expressed
and Secreted/ chemokine (C-C motif) ligand 5). Next, we proposed to examine the
migratory response of peritoneal macrophages to Acanthamoeba, and determine whether
THC affected this response. Finally, to expand the relevance of the previous studies we
assessed the effect of THC on the migration of primary rat microglial cells to
Acanthamoeba, thereby more closely modeling the process of a natural infection and
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identifying a potential mechanism of THC-induced immunosuppression in CNS
infections
We demonstrate that THC inhibits the chemotactic response of murine peritoneal
macrophages to RANTES, a cognate chemokine receptor ligand. The inhibitory effect
was shown to be linked functionally to the CB2, suggesting that cannabinoids can signal
through this receptor to trans-deactivate the chemokine receptor-mediated migratory
response. Additionally, we show that peritoneal macrophages and microglia, the
macrophages of the CNS, exhibit migration to Acanthamoeba and that this response is
inhibited by THC. While the immunosuppressive effects of THC are extensive and likely
involve numerous cell types and complex mechanisms and/or pathways, these studies
serve to define, at least in part, the mechanism by which THC suppresses macrophage
function.
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Materials and Methods

Amoeba
Acanthamoeba culbertsoni (American Type Culture Collection, ATCC 30171,
Manassas,VA) were cultured axenically in PYG medium containing 2% proteose
peptone, 0.2% yeast extract, and 0.1M glucose at 37 oC.
Acanthamoeba sp. strain JH1 was isolated from an immunosuppressed patient at
Johns Hopkins Hospital (Marciano-Cabral et al., 2003b). This clinical isolate was
obtained postmortem from a cutaneous lesion of an immune suppressed patient who had
undergone a prior renal transplant. Transmission electron microscopy studies identified
the presence of gram negative rods within the cytoplasmic vacuoles of the amoeba.
Acanthamoeba JH1 were cultured in Oxoid medium with serum and hemin and without
antibiotics.
Amoeba conditioned medium (ACM) was obtained by culturing amoeba in PYG
medium in 1L flasks at 37oC with constant agitation for 4 days. The amoebae were
harvested by centrifugation. The pelleted amoebae (109) were suspended in 5 ml Hank’s
Balanced Salt Solution (HBSS) and incubated at 37oC for 24 h. The following day the
cultures were centrifuged at 489 x g (2,500 RPM, Eppendorf 5810 R) for 20 min. The
supernatant was decanted and centrifuged again at 16100 x g (13,100 RPM, Eppendorf
5415 D) for 10 min to remove any remaining debris and was designated amoeba
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conditioned medium (ACM). Protein concentration of ACM was determined by
Bradford assay (Bradford, 1976).

Cells
Thioglycollate-elicited peritoneal macrophages were obtained by injecting
B6C3(F1) or C57BL/6 mice intraperitoneally with 1 ml 10% Brewer’s yeast
B

thioglycollate. Five days later, cells were harvested by aseptic peritoneal lavage with
HBSS supplemented with penicillin [200U/ml] and streptomycin [200 μg/ml]. The
peritoneal exudate cells were screened for purity for macrophages by FACScan analysis
using monoclonal antibody for the murine macrophage marker F4/80 (Serotec,
Kidlington, Oxford, UK). Cells that were greater than 95% positive for F4/80 were used
in studies. Macrophages (107 /ml) in RPMI 1640 medium (Cellgro, Herndon, VA)
lacking serum and supplemented with 1% L-glutamine, 1% nonessential amino acids, 1%
MEM vitamins, 0.01M HEPES and penicillin [100 U/ml]/streptomycin [100
μg/ml]/fungizone [0.25 μg/ml]) were used in chemotaxis assays.
Primary microglia cultures were prepared from neonatal Sprague-Dawley (ZivikMiller Laboratory, Zeleinople, PA) rat pups (1-2 days postpartum). Following sacrifice,
the cerebral cortices were isolated and placed in dissection saline containing 2.8% (v/v)
stock dissection HEPES (352mM HEPES in dH2O), 5% stock dissection saline (137 mM
NaCl, 5.3mM KCl, 0.17mM Na2PO4-7H2O, 0.22 mM KH2PO4, and 0.0012g/L Phenol
Red in dH2O), 5% stock Glucose/Sucrose solution (6g/L glucose, 15 g/L sucrose), and
penicillin [100 U/ml]/streptomycin [100 μg/ml]. Subsequently, the surrounding
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meninges were removed, the remaining tissue manually disrupted and incubated with
porcine pancreas derived trypsin (Sigma) for 10 min. The tissue homogenate was
suspended in DMEM containing 10% FBS and supplemented with 1% L-glutamine, 1%
nonessential amino acids, 1% MEM vitamins, 0.01M HEPES, and penicillin
(100U/mL)/streptomycin (100μg/mL) and fungizone (0.25 μg/mL) (complete DMEM)
and filtered through a 70μm nylon cell strainer. The strained suspension then was
centrifuged at 1,000 RPM for 30 min at 4oC. The mixed glial cell suspension containing
astrocytes and microglia were seeded in 172cm2 tissue culture flasks (Greiner, Monroe,
NC) and cultured at 37oC and 5% CO2 in complete DMEM medium. The medium was
replaced the following day with warmed complete DMEM and the cells allowed to grow
for 14-21 days. To recover primary microglia, the mixed glial cultures were agitated at
180 RPM on an orbital shaker for 2 h at 37oC. Alternately, primary rat mixed glial
cultures containing astrocytes and microglia were obtained from Dr. Jameel Dennis,
Department of Anatomy and Neurobiology following immunopanning using antioligodendrocyte antibodies to isolate oligodendrocytes from cortical cultures (Fox et al.,
2003).

Mice
Six to eight-week old female (B6C3)F1 and C57BL/6 mice were obtained from Taconic
Laboratories (Hudson, NY). CB2 (-/-) mice on a C57BL/6 background were obtained
from Dr. Nancy E. Buckley (California Polytechnic University, Pomona, CA). CB2
deficiency was confirmed by polymerase chain reaction (PCR) as described (Buckley et
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al., 2000; Chuchawankul et al., 2004). Phenotypic characterization was performed by
Buckley et al. (2000) and reportedly CB2 knockout mice are healthy and fertile with no
significant alterations in immune cell populations as measured by FACS analysis,
indicating that the knockout did not affect immune cell development or differentiation.
Therefore, peritoneal macrophages from these knockout mice should be phenotypically
comparable to wild type peritoneal macrophages and any effect, or absence thereof, of
cannabinoids on macrophage immune function should be the result of a measurable
scientific phenomenon and not an artifact.
Animals were quarantined for one week prior to initiation of experiments and
were used as a source of peritoneal macrophages. All animal procedures were conducted
in accordance with guidelines established by the Virginia Commonwealth University
Institutional Animal Care and Use Committee (IACUC).

Drugs
Delta-9-tetrahydrocannabinol (THC; CB1 Ki = 40.7nM; CB2 Ki= 36.4 nM), a low
efficacy agonist for CB1 and CB2, was obtained from the National Institute on Drug
Abuse (Rockville, MD). Additional cannabinoid analogs included the CB1 and CB2 high
efficacy agonist CP55940 (CB1 and CB2 Ki = 1.37 nM) and the highly selective CB2
ligand O-2137-2 (CB1 Ki = 2,700nM, CB2 Ki = 11nM). The highly selective CB1 agonist
ACEA (CB1 Ki = 1.4 nM) that displays > 1,400-fold selectivity over CB2 was purchased
B

from Tocris Cookson, Inc. (Ellisville, MO). The CB1 and CB2 antagonists SR141716
(CB1 Ki =11.8 nM, CB2 Ki = 13,200 nM) and SR144528 (CB1 Ki = 437nM, CB2 Ki =
0.6nM), respectively, were obtained from Sanofi Recherche (Montpellier, France).
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The review by Howlett et al. (2002) provides a comprehensive summary of cannabinoid
receptor ligand binding affinities and methodologies and was utilized in preparation of
Table 3. Ligand binding data was obtained from in vitro radiolabeled ligand
displacement assays performed on membrane preparations from either from cell lines
transfected with cloned receptors or tissues (brain tissue preparations for CB1 or spleen
tissue preparations for CB2).
B

Stock solutions of cannabinoids (10-2M) were prepared in 100% ethanol and
stored at –20oC. Experimental concentrations were obtained by dilution of cannabinoid
stock solutions in assay medium (RPMI-1640 for peritoneal macrophages or DMEM for
primary microglia) to yield a final ethanol concentration of 0.01%. Vehicle controls
consisted of 0.01% ethanol in medium.

Chemotaxis Assay
Chemotaxis was measured using transwell inserts pre-loaded in 35 mm standard
tissue culture plates (Corning Inc., Corning, NY), in which the upper and lower
compartments were separated by a polycarbonate filter with 8 μm pores (Corning Inc.,
Corning, NY). Peritoneal macrophages (1x107 /ml) were pre-incubated in RPMI 1640
lacking serum and containing vehicle (0.01% ethanol) or cannabinoid (10-6M – 10-12M)
for 3 h at 4oC. This time regimen for drug exposure was obtained through initial
optimization experiments. Serum was omitted from the culture medium since it contains
lipids and other factors that have the capacity to stimulate macrophage migration that
could confound interpretation of migratory responses as attributable to RANTES. For
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Table 3- Cannabinoid Receptor Ligands
Cannabinoid

Classification

Dissociation Constant (Ki)
CB1ki
CB2 ki

THC

Low efficacy CB1/CB2 agonist

40.7nM

36.4 nM

CP55940

High efficacy CB1 and CB2 agonist 1.37nM

1.37nM

ACEA

CB1 selective agonist

1.4nM

>2000nM

O-2137

CB2 selective agonist

2,700nM

11nM

SR141716A (SR1)

CB1 selective antagonist

11.8nM

13200nM

SR144528 (SR2)

CB2 selective antagonist

437nM

0.6nM

Abbreviations- THC, (δ9-tetrahydrocannabinol); CP55940, ((-)-cis-3-[2-Hydroxy-4-(1,1dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol); ACEA, (N-(2-Chloroethyl)5Z,8Z,11Z,14Z-eicosatetraenamide); O-2137, ((1R,3R)-1-[4-(1,1-Dimethylheptyl)2,6-dimethoxyphenyl]-3-methylcyclohexanol); SR141716A, (5-(4-Chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-N-(1-piperidyl)pyrazole-3-carboxamide); SR144528, ((1S-endo)-5-(4-Chloro-3methyl-phenyl)-1-((4methylphenyl)methyl)-N-(1,3,3-trimethylbicyclo(2.2.1)hept-2-yl)-1H-pyrazole-3carboxamide)

Adapted from Howlett et al., 2002
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experiments using antagonists, cells were exposed to SR141716A (SR1)(10-6M) or
SR144528 (SR2)(10-6M) for 30 min prior to treatment with THC or CP55940 for 3h.
Following vehicle or cannabinoid treatment, 100 μl of drug- or vehicle-treated cell
suspension (106cells) were placed in the upper chamber of the transwell insert. For
assessment of chemotaxis (directed migration against a chemokine concentration
gradient) the lower compartment was loaded (600μl) with medium containing murine
RANTES (1 ng/ml; R&D Systems, Minneapolis, MN). This concentration of RANTES
was selected based on preliminary titration for a chemoattractant response that
approximated a mid-point in the linear phase of the dose-response curve. For assessment
of chemokinesis (enhanced random migration to chemokine), RANTES (1 ng/ml) was
included in both the top and bottom chambers to eliminate the chemoattractant
concentration gradient. In addition, for a select number of experiments, RANTES was
eliminated from both chambers (Fig. 1). The assembled migration plate chamber system
was incubated (1-2 h) at 37oC in a 5%CO2 atmosphere. To determine the number of cells
that migrated to the bottom chamber, the upper chamber (i.e., polycarbonate filter) was
removed and video still images (1mm2) in five random fields of each bottom chamber
were captured using an Olympus CK2 inverted microscope (Opelco, Washington, DC)
with an attached XV-GP230 digital video camera (Panasonic, Yokohama, Japan)
interfaced to a Dell Dimension XPS1450 computer using Videum 100 hardware and
Window NT software (Winnov, Sunnyvale, CA). The number of cells migrating into the
bottom compartment/transwell plate was manually enumerated and calculated as the sum
of the five 1 mm2 fields and was represented as cells/mm2/well. Each sample group was
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Transwell
insert

Cells

Assay medium

Random
Migration

Cells

Chemoattractant

ChemotaxisDirectional
Migration

Cells +
Chemoattractant

Chemoattractant

ChemokinesisEnhanced Nondirectional
Migration

Figure 1- Transwell Migration Assay. Cells are loaded into transwell
inserts and assessed for migration to the bottom well. When the top and
bottom wells contain assay medium only, any migration is random. When
the bottom well contains a chemoattractant, cell migration occurs in
response to a concentration gradient. This migration, chemotaxis, is
compared to migration in which the chemoattractant substance is placed in
both the top and bottom wells. Under these conditiones, no concentration
gradient exists and any migration that occurs as a response to exposure to a
chemostimulus is called chemokinesis.
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run in duplicate and each experiment was performed in triplicate. Migration for each
sample group was represented as the mean (±SD) of the total number of migrating cells
counted in five fields of duplicate wells. A greater than 2-fold increase in cell migration
to the chemoattractant RANTES in the lower compartment as compared to that in the
absence of RANTES in the lower compartment was indicative of a positive response.

Immunoprecipitation of CCR5
Whole cell protein lysate (400 μg) in NP-40 lysis buffer containing protease
inhibitors was precleared for 30 min using 0.25μg normal mouse control IgG (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) and 20 μl Protein A/G Plus Agarose (Santa Cruz
Biotechnology). Precleared protein lysates were incubated with 2 μg CCR5 antibody
(CKR5 D6, Santa Cruz Biotechnology) for 2h at 4oC, followed by 12h incubation (4oC)
with Protein A/G PlusAgarose. The beads were collected by centrifugation (3000 RPM,
4oC, 1 min) and washed four times in room temperature phosphate-buffered saline. The
precipitates were resuspended in 40 μl electrophoresis sample buffer, heated for 3 min at
95oC, and resolved on a 10% SDS-polyacrylamide gel.

Isolation of Cannabinoid Receptor DNA from Plasmid Contructs
In order to obtain CB1 DNA to serve as a positive control in Real Time RT-PCR
assays, DH5α E.coli transfected with a pCD mammalian expression vector containing
SKR6 (rat CB1 DNA sequence) from Dr. L. Matsuda (Medical University of South
Carolina, Matsuda et al., 1990) were cultured in LB broth containing ampicillin (100
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μg/ml). The pCD-SKR6 plasmid was isolated using the Midi Prep Kit (Qiagen, Valencia,
CA). Following a restriction digest with EcoRI (Invitrogen) and BamHI (Invitrogen), the
cut plasmid was subjected to agarose gel electrophoresis (0.8% agarose gel; OmniPure
Agarose). The 2.4 kb fragment containing the rat CB1 DNA sequence was cut from the
agarose gel, isolated and purified using the QIAquick Gel Extraction Kit (Qiagen).
Purified CB2 DNA from the pUC18 vector containing murine CB2 sequence from
Dr. T. Bonner (NIMH, Bethesda, MD) was similarly obtained. Both purified CB1 and
CB2 DNA products were stored at –20oC in dH20 and the concentration determined using
a BioPhotometer (Eppendorf, Westbury, NY). Each product was sequenced at the MCVVCU Nucleic Acids Research Facility core lab using an Automated DNA sequencer.
DNA samples were further analyzed by BLAST (nucleotide-nucleotide BLAST, NCBI,
Bethesda, MD) to confirm sequence identity.

Multiprobe Ribonuclease Protection Assay
Total RNA prepared from peritoneal macrophages using TRIzol reagent
(Invitrogen, Carlsbad, CA) was redissolved after isopropanol precipitation directly in 1X
hybridization buffer (BD Biosciences/PharMingen, San Diego, CA). A Riboquant Multiprobe Ribonuclease Protection Assay (RPA) was used to assess for levels of murine
chemokine receptor mRNA (mcr-5 probe template set; BD Biosciences/PharMingen).
The ribo-probes were labeled with 32P[UTP] (MP Biomedicals, Aurora, OH) to a specific
activity of greater than 3,000Ci/mmol. The isolated RNA samples then were hybridized
with the probe overnight at 56oC and the protected fragments were resolved on a 6%
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polyacrylamide gel containing 6M urea. Imaging of the protected fragments was
performed using a 445 SI Phosphorimager (Molecular Dynamics, Sunnyvale, CA). The
pixel intensity of each band was quantified using ImageQuant 4.1 software (Molecular
Dynamics) and the amount of chemokine receptor mRNA was normalized for loading by
dividing the pixel value for the chemokine receptor band by the sum of the pixel values
for the mRNAs of the housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and a ribosomal protein, L32.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Real–time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), using
SYBR Green for detection and primers for CB1 and CB2 and GAPDH, was used to assess
for the presence of CB1 and CB2 mRNA, and for constitutively expressed GAPDH
mRNA, respectively. Total RNA from peritoneal macrophages was prepared using
TRIzol reagent (Invitrogen) according the manufacturer’s instructions. The RNA then
was isolated by chloroform:isopropanol extraction and resuspended in 50 μl PCR grade
water. The isolated RNA was treated with RNase-free DNase I Amplification grade
(Invitrogen) to remove residual genomic DNA. The reverse transcription (RT) step was
performed in a Bio-Rad iCycler (BioRad, Richmond, CA) using the SuperScript III FirstStrand Synthesis System (Invitrogen) that included random hexamers as primer to
generate complementary DNA (cDNA). SYBR Green real-time PCR was performed
using the RT2 PCR Primer Set for mouse CB1 (Cnr 1: PPM04603A) or CB2 (Cnr 2:
PPM04826A) and GAPDH (GAPDH:PPM02946A) as described by the manufacturer
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(SuperArray Bioscience Corp., Frederick, MD). Briefly, each 25 μl PCR mix consisted
of 12.5 μl 2X RT2 Real-Time SYBR Green PCR Master Mix (SuperArray), 1.0 μl first
strand cDNA template, and 1.0 μl RT2 PCR Primer Set brought to a final volume of 25 μl
with DEPC-treated water. Tubes containing the PCR mix were placed in a SmartCycler
(Cepheid, Sunnyvale, CA) and PCR was performed using the following program: 95oC,
15 min; 40 cycles of (95oC, 30 sec; 55oC, 30 sec; and 72oC, 30 sec). The resulting PCR
products were visualized by electrophoresis (100V) using 4% OmniPur Agarose PCR
Plus (VWR, West Chester, PA) gel in 1X Tris-Borate-EDTA (TBE) buffer. A pCD- and
a pUC18-mCB2 plasmid template served as positive PCR controls for CB1 and CB2,
respectively. Using this approach, amplification products of 167 bp and 207 bp were
generated for CB1 and CB2, respectively.

Scanning Electron Microscopy
Transwell inserts containing polycarbonate filters with 8 μm pores were removed
from the chemotaxis plates. The top and bottom sides of the filter were washed gently to
remove non-adherent cells and fixed with 2.5% gluteraldehyde. Post-fixation with
2%OsO4 was followed by dehydration in a graded series of alcohol washes (Pettit et al.,
1996). The filters containing adherent macrophages were subjected to critical point
drying, coated with gold and viewed with a JEOL scanning electron microscope (20kV).

23

SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Immunoblotting
Peritoneal macrophages were washed with room temperature PBS (2x) then
incubated in NP-40 lysis buffer containing Protease Inhibitor Cocktail (100:1) (Sigma, St.
Louis, MO; 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E-64, bestatin,
leupeptin, aprotinin) for 30 min on ice. The cell lysates were centrifuged at 10,000 x g
for 15 min, at 40C. The pellets then were discarded, the supernatants containing cellular
proteins saved, and concentrations were determined by the Bradford assay. Protein
samples (40 μg/sample) were separated on a 12% polyacrylamide gel and transferred to a
Transblot Transfer nitrocellulose membrane (BioRad, Hercules, CA). The membranes
were incubated individually with anti-CCR1, anti-CCR5, and anti-CB2 antibody. The
antibody to CCR1 (CKR1 H-52 rabbit polyclonal IgG, Santa Cruz Biotechnology) was
directed against the extracellular amino terminus whereas the antibody to CCR5 (CKR5
D-19 mouse monoclonal IgG, Santa Cruz Biotechnology) was directed against the
carboxy terminal domain. The antibody to CB2 (CB2 M15 goat polyclonal IgG, Santa
Cruz Biotechnology) was raised against peptide mapping of the C terminus of mouse
CB2.

Statistical Analysis
Analysis of variance (ANOVA) was performed using Dunnett’s test and was
followed by a Student’s t-test to allow for comparison of each sample to the vehicle.
Comparisons between treatment groups were performed using Bonferroni’s t test.
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Results
Murine Thioglycollate-Elicited Peritoneal Macrophages Express the Chemokine
Receptors CCR1 and CCR5 and the Cannabinoid Receptor CB2
RANTES binds to the chemokine receptors CCR1, CCR3, and CCR5 (Murphy,
2002; Bajetto et al., 2002; Charo et al., 2006). Thus, in order to determine the CC
chemokine receptor gene expression profile of (B6C3)F1 and C57BL/6 murine
thioglycollate-elicited peritoneal macrophages, a multiprobe RNase Protection assay was
employed. Using a template set for CC chemokine receptors, it was demonstrated that the
predominant chemokine receptor mRNAs detected for (B6C3)F1 mice were those for
CCR1, CCR2 and CCR5 (Fig. 2). C57BL/6 mice contained approximately equal levels of
mRNA for CCR1 and CCR5 but, in contrast to (B6C3)F1 mice, contained low levels of
mRNA for CCR2. Because RANTES is a major agonist for CCR1 and CCR5, but not
CCR2, the presence of protein for the former two receptors also was determined (Fig. 3).
Consistent with the mRNA data, approximately equivalent levels of protein for CCR1 and
CCR5 were detected in thioglycollate-elicited macrophages of (B6C3)F1 and C57BL/6
mice.
SYBR Green RT-PCR was employed to assess for the presence of CB2 mRNA in
peritoneal macrophages from (B6C3)F1 and C57BL/6 mice. Prior to performing PCR,
CB1 and CB2 cDNA was isolated from plasmid preparations of DH5α E. coli that had
been transfected with mammalian expression vectors containing CB1 and CB2 DNA
sequences (pCD-rSKR6 and pUC18-mCB2, respectively) for use as positive controls in
Real-time RT-PCR. The isolated plasmids were digested with restriction enzymes EcoRI
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CCR1

CCR5

Figure 2 – CCR1 and CCR5 mRNA Are Expressed by Peritoneal
Macrophages. RNase Protection Assay demonstrated that peritoneal
macrophages express predominantly CCR1 and CCR5, with low levels of
CCR2 expression. P- Undigested probe, Y- yeast control (-), M- mouse
control (+), 1-(B6C3)F1 peritoneal macrophages, 2- C57BL/6 peritoneal
macrophages, 3- CB2 -/- BM cell line (Raborn et al., 2007).
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Figure 3– Peritoneal Macrophages Express CCR1, CCR5, and CB2 at the
Protein Level. Whole cell lysates from (B6C3)F1 and C57BL6 murine
peritonal macrophages were separated by SDS-PAGE followed by Western
immunoblot analysis with antibodies to CCR1, CCR5, and Actin. B6(B6C3)F1, C57- C57BL/6
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and BamHI to release cannabinoid receptor DNA sequences. The digests were subjected
to agarose gel electrophoresis and CB1 and CB2 DNA was extracted from the gel and
purified (Fig. 4)(CB1 fragment 2.4kb, CB2 fragment 1.3kb). A 207 bp amplicon,
consistent with the fragment size predicted for the CB2, was detected from total RNA of
peritoneal macrophages (Fig. 5). Western immunoblot analysis using a murine CB2
domain-specific antibody confirmed the presence of CB2 in murine peritoneal
macrophages at the protein level (Fig. 3). Furthermore, using SYBR Green RT-PCR
(Fig. 5) and Western immunoblot analysis (Data not shown) the absence of CB1 mRNA
or protein expression in thioglycollate-elicited peritoneal macrophages from (B6C3)F1
and C57BL/6 mice was demonstrated.

Treatment with THC in vivo Results in Inhibition of the Chemotactic Response of Murine
Peritoneal Macrophages to RANTES in vitro.
(B6C3)F1 mice were inoculated with thioglycollate and 5 days later were
administered a single intraperitoneal injection of vehicle (ethanol:emulphor:saline,
1:1:18) or THC (25 mg/kg or 50 mg/kg). Peritoneal macrophages were harvested 24h
later and were subjected to migration assay. In vivo administration of 25 mg/kg or 50
mg/kg THC resulted in a significant and greater than 50% inhibition of cell migration in
response to RANTES as compared to that observed for cells of mice receiving vehicle
(Fig. 6). No significant differences in migration were obtained between vehicle and drug
treated cells when RANTES was placed in both the top and bottom compartments to
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Figure 4- Generation of Real-time RT-PCR CB1 and CB2 positive control
DNA. pUC18-mCB2 was digested with EcoR1 and BamH1 to release
mCB2 DNA (1.3 kb). B. pCD-sKR6 (rCB1)was digested with EcoR1 and
BamHI to release 2.4 kb fragment of rCB1 DNA.
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200bp
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Figure 5- Cannabinoid Receptor mRNA Expression by Peritoneal
Macrophages. Real-time RT-PCR demonstrated that peritoneal macrophages
express primarily CB2 mRNA. CB1 and CB2 DNA as well as GAPDH were
used as positive controls.

cells x 103/mm2/well

30

1 ng/mL RANTES
4
3
2
1

**

VEH

**

25
50
mg/kg THC

VEH

25
mg/kg THC

Figure 6- Treatment in vivo with THC Results in Inhibition of the Chemotactic
Response to RANTES. (B6C3)F1 mice were injected intraperitoneally with 10%
thioglycollate to elicit macrophages. Five days later, the mice were injected
intraperitoneally with vehicle (VEH) (1:1:18, ethanol:emulphor:saline) or THC (25
mg/kg or 50 mg/kg). Migration of macrophages to 1ng/ml RANTES was assessed in
vitro using transwell tissue culture inserts. Results are presented as the mean ± SD.
For RANTES placed only in the bottom chamber, SD was compared with that of
vehicle-treated macrophages exposed to RANTES in the bottom chamber. For
RANTES placed in both chambers (shaded bars), SD was compared with that of
vehicle-treated macrophages exposed to RANTES in both chambers. When RANTES
was added only to the bottom compartment, THC as compared to the vehicle control
exerted a major inhibitory effect on cell migration to the bottom compartment. When
RANTES was added to both the upper and lower compartments to eliminate the
chemoattractant concentration gradient, THC as compared to the vehicle control did
not result in significant inhibition of cell migration to the bottom well. These results
indicate that THC inhibits directed migration (i.e., chemotaxis) to a RANTES
concentration gradient rather enhancement of random movement (i.e., chemokinesis)
to RANTES. **p<0.01.
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eliminate the RANTES concentration gradient. These results are consistent with THC as
exerting an inhibitory effect on the macrophage chemotactic response to RANTES.

Treatment with THC and CP55940 in vitro Results in Inhibition of the Chemotactic
Response of Murine Peritoneal Macrophages to RANTES
In order to determine whether THC exerted a direct effect on macrophages, in
vitro exposure experiments were performed. THC treatment of (B6C3)F1 murine
peritoneal macrophages in vitro resulted in a significant inhibition of the chemotactic
response to RANTES (Fig. 7). Cells treated with vehicle exhibited a minimal level of
migration (i.e., approximately 1,600 cells/mm2/well) to the bottom compartment in the
absence of RANTES. In contrast, when RANTES was added to the bottom compartment
to establish a chemokine concentration gradient, a nearly five-fold increase (i.e., in excess
of 5,000 cells/mm2/well) was obtained for macrophages treated with vehicle. Treatment
of macrophages with THC (10-6M – 10-12M) resulted in a significant inhibition of
migration in response to RANTES. THC, at a concentration as low as 10-12M, exerted a
major inhibitory effect on cell migration, with numbers of cells in the bottom
compartment approximating those for cells treated with vehicle and not exposed to
RANTES. Again, the inhibitory effect of THC on macrophage migration was at the level
of chemotaxis rather than chemokinesis. When RANTES was added to both the upper
and lower compartments to eliminate the chemoattractant concentration gradient to allow
for assessment of random migration to chemokine, approximately 1,000 cells/mm2/well
were obtained for peritoneal macrophages treated with vehicle. Treatment of these cells
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Figure 7 - Treatment in vitro with THC Results in Inhibition of the Chemotactic
Response to RANTES. A. Migration of peritoneal macrophages to 1ng/ml
6
12
RANTES was assessed following in vitro treatment (3h) with THC (10- to 10M) or vehicle (VEH) (0.01% ethanol). Treatment with the partial agonist THC
resulted in inhibition of chemotaxis. Results are presented as the mean ± SD. For
RANTES placed only in the bottom chamber, SD was compared with that of
vehicle-treated macrophages exposed to RANTES in the bottom chamber. For
RANTES placed in both chambers (shaded bars), SD was compared with that of
vehicle-treated macrophages exposed to RANTES in both chambers. *p<0.05,
**p<0.01, ***p<0.001. B. Results presented as Percent Inhibition of migration.
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with 10-8M or 10-11M THC did not result in significant inhibition of this random
movement. Rather, a slight augmentation in random migration to the bottom compartment
was recorded.
Experiments performed with THC were replicated using CP55940, a high efficacy
agonist at CB1 and CB2 (Fig. 8). Again, a minimal level in cell migration was observed
for control wells. Approximately 1,500 cells/mm2/well were recorded when vehicletreated cells were placed in the top compartment in the absence of RANTES in the
bottom compartment. An approximate four-fold increase in the number of peritoneal
macrophages treated with vehicle was obtained when RANTES was placed in the bottom
compartment to establish a chemoattractant gradient. Treatment of cells with CP55940
(10-6M – 10-12M) resulted in a significant concentration-related decrease in migration in
response to RANTES. A greater than 50% inhibition in migration was obtained for cells
treated with CP55940 at 10-6M – 10-9M as compared to vehicle control. CP55940 as
compared to vehicle did not affect macrophage migration when RANTES was placed
both in the top and bottom compartments to eliminate the chemoattractant gradient,
indicating that the effect of CP55940 on migration was at the level of chemotaxis rather
than chemokinesis.
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Figure 8- Treatment in vitro with CP55940 Results in Inhibition of the Chemotactic
Response to RANTES. A. Migration of peritoneal macrophages to 1ng/ml RANTES was
6
12
assessed following in vitro treatment (3h) with CP55940 (CP) (10- to 10- M) or vehicle
(VEH) (0.01% ethanol). Treatment with the full agonist CP55940 resulted in a robust
dose-related inhibition of chemotaxis to RANTES. Results are presented as the mean ±
SD. For RANTES placed only in the bottom chamber, SD was compared with that of
vehicle-treated macrophages exposed to RANTES in the bottom chamber. For RANTES
placed in both chambers (shaded bars), SD was compared with that of vehicle-treated
macrophages exposed to RANTES in both chambers. *p<0.05, **p<0.01. B. Results
presented as Percent Inhibition of Migration.
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The CB2-selective Ligand O-2137 Exerts a Robust Inhibitory Effect on the Murine
Peritoneal Macrophage Chemotactic Response to RANTES
The concentration-related inhibitory effect most evident using CP55940 on the
chemotactic response of murine peritoneal macrophages to RANTES implicated a role
for a cannabinoid receptor in this process. In order to obtain insight as to the cannabinoid
receptor linked to the inhibitory effect, macrophages from (B6C3)F1 mice were treated
with compounds exhibiting selective high affinity binding to the CB1 or the CB2 prior to
assessment of the chemotactic response to RANTES. Treatment of macrophages with the
highly selective CB2 ligand O-2137 resulted in a profound and significant concentrationrelated inhibition in the chemotactic response to RANTES (Fig. 9). For drug
concentrations of 10-6M – 10-8M, a greater than 50% inhibition, as compared to vehicle
control, was observed. In contrast, the CB1 specific ligand ACEA (10-6M – 10-12M)
exerted a minimal inhibitory effect on the peritoneal macrophage chemotactic response to
RANTES (Fig. 10).
The CB2-specific Antagonist SR144528 Reverses the Inhibitory Effect of CP55940 on the
Murine Peritoneal Macrophage Chemotactic Response to RANTES
In order to confirm the data indicating that activation of the CB2 with a
B

cannabinoid receptor selective ligand exerted a major inhibitory effect on the chemotactic
response to RANTES, cannabinoid receptor agonist-antagonist experiments were
performed. For these experiments, the CB1 or CB2 antagonist was used at a concentration
of 10-6M. Treatment of (B6C3)F1 murine peritoneal macrophages with the CB2-specific
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Figure 9- Effect of the CB2-selective Ligand on the Chemotactic Response to
RANTES. A. Treatment (3h) with the CB2-selective ligand O-2137 resulted in a
robust and significant inhibition of chemotaxis. Results are presented as the mean ±
SD. For RANTES placed only in the bottom chamber, SD was compared with that
of vehicle-treated macrophages exposed to RANTES in the bottom chamber. For
RANTES placed in both chambers (shaded bars), SD was compared with that of
vehicle (VEH)-treated macrophages exposed to RANTES in both chambers.
*p<0.05, **p<0.01. B. Results presented as Percent Inhibition of migration.
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Figure 10- Effect of the CB1-selective Ligand on the Chemotactic Response to RANTES.
A. Treatment with the CB1-selective ligand ACEA had a minimal effect on RANTESinduced migration of peritoneal macrophages. Results are presented as the mean ± SD.
For RANTES placed only in the bottom chamber, SD was compared with that of vehicle
(VEH)-treated macrophages exposed to RANTES in the bottom chamber. For RANTES
placed in both chambers (shaded bars), SD was compared with that of vehicle-treated
macrophages exposed to RANTES in both chambers. *p<0.05. B. Results presented as
Percent Inhibition of migration.
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antagonist SR144528 (SR2) alone had no major effect on the chemotactic response to
RANTES. At equimolar concentrations (i.e., 10-6M) of antagonist and agonist, CP55940
inhibited macrophage chemotaxis to RANTES. However, at lower concentrations of
CP55940 (10-7M – 10-11M), the inhibitory effect of the agonist was reversed by the CB2
B

antagonist SR144528 (Fig. 12). These results were in direct contrast to those obtained
when the CB1 antagonist SR141716A (SR1) was used (Fig. 11). Treatment with SR1
(10-6M – 10-12M) did not block the inhibitory effect of CP55940.

THC Does Not Inhibit the Chemotactic Response to RANTES of Peritoneal Macrophages
from CB2 Knockout Mice
To confirm the pharmacological data implicative of a functional linkage of the
CB2 to cannabinoid-mediated inhibition of macrophage chemotaxis to RANTES,
experiments were performed using thioglycollate-elicited peritoneal macrophages from
C57BL/6 CB2 knockout mice. THC (10-5M – 10-9M) had no significant effect on either
the chemotactic or chemokinetic response of macrophages from the knockout mice (Fig.
13). Since these CB2 null animals were generated on a C57BL/6 genetic background,
replicate migration experiments were performed using thioglycollate-elicited peritoneal
macrophages from their C57BL/6 CB2 (+/+) wild-type counterparts. Consistent with the
data obtained using (B6C3)F1 mice, THC exerted a concentration-related inhibition of the
chemotactic response of peritoneal macrophages to RANTES (Fig. 14).
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Figure 11- Effect of CB1 Cannabinoid Receptor Antagonist on Chemotaxis to
6
RANTES. Treatment with the CB1 antagonist SR141716A (SR1)(10- M) did not
block CP55940 (CP)-mediated inhibition of chemotaxis. Macrophages were
treated (30 min) with antagonist prior to treatment (3h) with cannabinoid. Results
are presented as the mean ± SD. For RANTES placed only in the bottom chamber,
SD was compared with that of vehicle (VEH)-treated macrophages exposed to
RANTES in the bottom chamber. For RANTES placed in both chambers (shaded
bars), SD was compared with that of vehicle-treated macrophages exposed to
RANTES in both chambers. *p<0.05, **p<0.01.
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Figure 12- Effect of CB2 Cannabinoid Receptor Antagonist on Chemotaxis to
RANTES. The CP55940 (CP)-mediated inhibition of chemotaxis was reversed by
6
SR144528 (SR2)(10- M). Macrophages were treated (30 min) with antagonist prior
to treatment (3h) with cannabinoid. Results are presented as the mean ± SD. For
RANTES placed only in the bottom chamber, SD was compared with that of vehicle
(VEH)-treated macrophages exposed to RANTES in the bottom chamber. For
RANTES placed in both chambers (shaded bars), SD was compared with that of
vehicle-treated macrophages exposed to RANTES in both chambers. *p<0.05,
**p<0.01, ***p<0.001.
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Figure 13- Effect of THC on the Chemotactic Response of Peritoneal
Macrophages from CB2 Knockout Mice to RANTES. In vitro THC treatment (3h)
did not have a significant effect on RANTES-induced migration by peritoneal
macrophages from CB2 receptor knockout mice. Results are presented as the mean
± SD. For RANTES placed only in the bottom chamber, SD was compared with
that of vehicle (VEH)-treated macrophages exposed to RANTES in the bottom
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Figure 14- Effect of THC on the Chemotactic Response of Peritoneal Macrophages from
the Wild-type Counterpart. THC treatment (3h) resulted in a concentration-related
inhibition of the chemotactic response of peritoneal macrophages to RANTES from the
C57BL/6 CB2 (+/+) wild-type counterpart. Results are presented as the mean ± SD. For
RANTES placed only in the bottom chamber, SD was compared with that of vehicle
(VEH)-treated macrophages exposed to RANTES in the bottom. *p<0.05, **p< 0.01,
***p<0.001
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THC Alters Functional Morphology of Murine Peritoneal Macrophages Undergoing
Chemotaxis to RANTES
Transwell chemotaxis assays revealed that THC inhibits peritoneal macrophage
migration to RANTES. Scanning electron microscopy analysis of the transwell
membranes demonstrated that cells treated with THC exhibited altered morphology and
were apparently impaired in their ability to migrate through the pores into the bottom
chamber containing the chemoattractant. Vehicle-treated (0.01% Ethanol) peritoneal
macrophages exposed to RANTES exhibited characteristics indicative of cell migration
including cell membrane ruffling and lobose cellular extensions (pseudopodia formation)
(Fig. 15). Additionally, numerous vehicle-treated macrophages were found in or in close
proximity to the membrane pores with pseudopodia extending toward the pore (Fig. 15).
In contrast, peritoneal macrophages treated with THC were rounded in appearance, with
the absence of cellular extensions. Few THC-treated macrophages were observed close
to or in filter pores.

THC Does Not Alter mRNA Levels of CC Chemokine Receptors in Thioglycollate-Elicited
Murine Peritoneal Macrophages
Chemotaxis to RANTES results from a complex series of signal transductional
activities following ligation of the chemokine to its cognate G protein-coupled receptor.
THC treatment of macrophages could affect activation of chemokine receptors and alter
their expression and/or compartmentalization. Thus, in order to obtain initial insight as to
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Figure 15– THC Alters the Morphology of Peritoneal Macrophages
Migrating to RANTES. Scanning electron microscopy of transwell inserts
of peritoneal macrophages treated with Vehicle (0.01% Ethanol) migrating
towards 1ng/ml RANTES (note multiple cellular projections). Cells
treated with THC are rounded in appearance and do not seem to be
migrating toward RANTES. Scale bars 1, 10, and 10 mm left to right.
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the mode of action through which THC treatment results in inhibition of chemotaxis,
experiments were performed to assess for levels CC chemokine mRNA in peritoneal
macrophages. THC (10-6M -10-12M) treatment of (B6C3)F1 peritoneal macrophages (3h)
had no major effect on total mRNA levels of CCR1, CCR2 or CCR5 (Fig. 16).
Additionally, treatment with a battery of cannabinoid receptor agonists and antagonists
(THC, CP55940, SR1, and SR2 at 10-6M) also had no major effect on chemokine
receptor mRNA levels (Fig. 17). Chemokine receptor mRNA levels also were assessed
for peritoneal macrophages exposed to THC in vivo (50mg/kg THC for 24h prior to
harvest of peritoneal macrophages). Consistent with results obtained in vitro, THC
treatment had no major effect on the expression of CCR1, CCR2, or CCR5 at the level of
total mRNA (Data not shown). Similarly, at this concentration range THC had no major
effect on total mRNA levels of CB2 (Data not shown).
Heterologous Desensitization of Chemokine Receptors by Cannabinoids
G-protein coupled receptors display reduced responsiveness with prolonged or
repeated agonist stimulation, a process known as receptor desensitization. Upon
phosphorylation by G-protein receptor kinases (GRKs) receptor internalization and
recycling is initiated. In cell types expressing numerous classes of G-protein coupled
receptors, signaling through one class of GPCR has been shown to trans-deactivate other
receptor types through heterologous desensitization. It is therefore possible that
cannabinoid treatment could affect chemokine receptor function, resulting in reduced
responsiveness to chemokines. In order to obtain insight regarding whether cannabinoid
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Figure 16- Effect of THC on Levels of CC Chemokine Receptor mRNA.
6
Multiprobe ribonuclease protection assay demonstrated that THC (10- M –
12
10- M) treatment (3h) had no major effect on levels of CCR1, CCR2, and
CCR5 mRNA in thioglycollate-elicited (B6C3)F1 murine peritoneal
macrophages.
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Figure 17- Effect of Select Cannabinoids on Levels f CC Chemokine
Receptor mRNA. Multiprobe ribonuclease protection assay demonstrated
that THC, CP55940, SR1, or SR2 (10-6 M) treatment (3h) had no major
effect on levels of CCR1, CCR2, and CCR5 mRNA in thioglycollateelicited (B6C3)F1 murine peritoneal macrophages.
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treatment caused heterologous desensitization of chemokine receptors, experiments were
performed to assess levels of CCR5 phosphorylation following stimulation with
RANTES or CP55940. Treatment of peritoneal macrophages with cognate ligand
RANTES (1ng/ml) (1h) resulted in increased CCR5 phosphorylation compared to vehicle
(Fig. 18). CP55940 treatment also enhanced CCR5 phosphorylation, though not to the
same extent as the cognate agonist, indicating that heterologous desensitization of
chemokine receptors by cannabinoids may be occurring.

Endogenous Cannabinoid 2-Arachidonylglycerol (2-AG) Induces Murine Peritoneal
Macrophage Migration
Numerous groups have reported that select cannabinoids are capable of inducing
migration in a variety of immune cell types including microglia and cell lines of myeloid
origin (Walter et al., 2003; Jordá et al., 2002; Kishimoto et al., 2005); however, to date
there have been no published reports specifically utilizing primary macrophages from the
periphery. To address this, experiments were performed to assess the ability of the
endogenous cannabinoid, 2-AG (1 nM to 5 μM) to induce peritoneal macrophage
migration. Maximal macrophage migration was observed using 1μM 2-AG (Fig. 19),
consistent with data obtained using other cell types.
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Figure 18– Stimulation with RANTES and Cannabinoid Receptor
Agonist CP55940 Induces CCR5 Phosphorylation. Peritoneal
macrophages were treated for 1h with vehicle, RANTES (1ng/ml), or
-6
CP55940 (10 M) and harvested for protein. Whole cell protein lysates
of peritoneal macrophages were precleared with normal mouse IgG. A
CCR5 antibody was used to immunoprecipitate CCR5 from the
precleared protein lysate. Following SDS-PAGE, the immunoblot (A.)
was probed with an antiphosphoserine antibody to detect CCR5
phosphorylation. B. Densitometric analysis of CCR5 phosphorylation.
V-vehicle, R- RANTES, CP-CP55940.
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Figure 19 – The Endogenous Cannabinoid 2-AG Induces Peritoneal Macrophage
Chemotaxis. Transwell chemotaxis assay was utilized to assess chemoattractant
properties of 2-AG (4h) (0.01-5 μΜ). Results are presented as mean ± SD.
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Treatment with THC Inhibits Murine Peritoneal Macrophage Migration to 2-AG
Further experiments were performed to address whether treatment with THC
could inhibit peritoneal macrophage chemotaxis to 2-AG. Treatment of macrophages
with THC (10-6M – 10-8M) resulted in a significant inhibition of migration in response to
2-AG (Fig 20).

Migration of Murine Peritoneal Macrophages to Amoebic Conditioned Medium
In studies using an in vivo murine model of Acanthamoeba infection, MarcianoCabral and Cabral (2003) demonstrated that macrophage-like cells are the primary
immune cell component in granulomas, which are formed in response to amoebic
infection. It has been proposed that these granulomas may serve to sequester the ameba,
thereby preventing further dissemination (Fig. 21). Additionally, exposure to THC
exacerbated Acanthamoeba infection, characterized by increased mortality and numbers
of amoeba present in brain sections, as well as the absence of granuloma formation (Fig.
21). Acathamoeba infection notably results in dramatic and extensive tissue damage,
which occurs through a combination of direct contact and the secretion of numerous lytic
enzymes (Table 4). Experiments, therefore, were performed to assess peritoneal
macrophage migration to amebic conditioned medium (0-72 μg) obtained from cultures
incubated with Acanthamoeba culbertsoni (AcCM) and Acanthamoeba (JH1) (JH1CM),
a clinical isolate containing intracellular bacteria. Amebic conditioned medium from A.
culbertsoni (Fig. 22) and JH1 isolate (similar results, data not shown) induced
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Figure 20– THC Inhibits Peritoneal Macrophage Chemotaxis to 2-AG.
Peritoneal macrophages were treated with THC (10-6 -10-12 M) for 3 h and then
assessed for chemotaxis to 1 μM 2-AG (2h). VEH- vehicle (0.01% ethanol).
*p<0.05, **p<0.01.
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A.

B.

Figure 21– A. Hematoxylin and Eosin (H&E) Stained Section of Paraffinembedded Brain Tissue Demonstrating Granuloma Formation in Acanthamoeba
infection. B. Sections of paraffin-embedded brain tissue demonstrating granuloma
formation in Acanthamoeba infection. Top panel- Vehicle treated mouse. Bottom
panel- THC-treated mouse. Images courtesy of Marciano-Cabral and Cabral 2003
and Cabral et al., 2007.
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Table 4- Acanthamoeba Secreted Factors
Product

Action

Reference

Serine Protease (33 kD)

degrades IgG and IgA

Kong et al., 2000

Lytic enzymes

involved in invasion

Moore et al., 1991
Alfieri et al., 2000

Serine and cysteine
proteinases

markers for pathogenicity

Hadas and Mazur
1993

Serine, cysteine and
metalloproteinases

degrade type I collagen

Mitro et al., 1994

Serine protease (42kD)

degrades collagen

Cho et al., 2000

Serine protease (33kD)

implicated in virulence

Kim et al., 2006

Serine protease (85,130kD)

degrades types I and III collagen Sissons et al., 2006
elastin, plasminogen, casein,
and hemoglobin

Metalloprotease (150kD)

degrades types I and III collagen
elastin, plasminogen, casein,
and hemoglobin
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Figure 22 – Peritoneal Macrophages Migrate in Response to Amoebic
Conditioned Medium. Transwell migration assays (2h) were performed
to assess peritoneal macrophage migration to Acanthamoeba conditioned
medium (Acanthamoeba culbertsoni- 0-72 μg).
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macrophage migration with a greater than 2-fold increase observed at concentrations of
conditioned medium as low as 36μg.

Treatment with THC Inhibits the Chemotactic Response of Murine Peritoneal
Macrophages to Amoebic Conditioned Medium
In order to determine whether THC exerted a direct effect on macrophage
migration to amebic conditioned medium, in vitro exposure experiments were performed.
A minimal level of cell migration was observed for control wells. An approximate threefold increase in the number of peritoneal macrophages treated with vehicle was obtained
when amoebic conditioned medium was placed in the bottom compartment to establish a
chemoattractant gradient. Treatment of cells with THC (10-6-10-10M) resulted in a
significant concentration-related decrease in migration in response to Acanthamoeba
(JH1) conditioned medium (JH1CM; 36μg) (Fig. 23). Similarly, treatment of cells with
THC (10-6-10-11M) resulted in a significant concentration-related decrease in migration in
response to Acanthamoeba culbertsoni conditioned medium (AcCM; 36μg) (Fig. 24).

Treatment with THC in vivo Results in Inhibition of Murine Peritoneal Macrophage
Migration to Amoebic Conditioned Medium in vitro
(B6C3)F1 mice were inoculated with vehicle (ethanol:emulphor:saline, 1:1:18) or
THC (5, 10, 25 or 50 mg/kg) (one injection per day for 4 days). On the last day of
injections, thioglycollate was administered and 5 days later peritoneal macrophages were
harvested. Migration assays were performed to assess the effect of in vivo THC exposure
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Figure 23– THC Inhibits Peritoneal Macrophage Chemotaxis to Acanthamoeba
Condtioned Medium. Peritoneal macrophages were treated with THC (10-610-12 M) for 3h and then assessed for migration to 36 μg Acanthamoeba (JH1)
conditioned medium (1h). *p<0.05, ***p<0.001. VEH- vehicle (0.01%
ethanol).
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Figure 24– THC Inhibits Peritoneal Macrophage Chemotaxis to
Acanthamoeba Conditioned Medium. Peritoneal macrophages were
treated with THC (10-6- 10-12 M) for 3h then assessed for migration to 36
μg Acanthamoeba culbertsoni conditioned medium (AcCM) for 1h.
Results are presented as mean ± SD. **p<0.01, ***p<0.001. VEHvehicle (0.01% ethanol).
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on in vitro migration to amoebic conditioned medium. In vivo administration of 10
mg/kg or 25 mg/kg THC resulted in a significant and greater than 50% inhibition of cell
migration to Acanthamoeba culbertsoni conditioned medium (AcCM; 36μg) (Fig. 25).

Treatment with CP55940 Inhibits the Chemotactic Response of Murine Peritoneal
Macrophages to Amoebic Conditioned Medium
Experiments performed with THC were replicated using CP55940, a high efficacy
agonist at CB1 and CB2. Treatment of cells with CP55940 (10-6-10-10 and 10-12 M)
resulted in a significant concentration-related decrease in chemotaxis in response to
Acanthamoeba (JH1) conditioned medium (JH1CM; 36μg) (Fig. 26). Greater than 50%
inhibition of cell migration to amebic conditioned medium was observed with CP55940
treatment at concentrations of 10-6-10-10M compared to vehicle-treated macrophages.

The CB2-selective Ligand O-2137 Exerts a Robust Inhibitory Effect on the Murine
Peritoneal Macrophage Chemotactic Response to Amoebic Conditioned Medium
In order to determine whether a cannabinoid receptor was linked to the observed
inhibitory effect, macrophages from (B6C3)F1 mice were treated with compounds
B

exhibiting selective high affinity binding to the CB1 or the CB2 prior to assessment of the
chemotactic response to amoebic conditioned medium. Treatment of macrophages with
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Figure 25- In vivo Exposure to THC Inhibits Peritoneal Macrophage
Chemotaxis to Acanthamoeba Conditioned Medium. (B6C3)F1 mice were
inoculated with vehicle (VEH) (ethanol:emulphor:saline, 1:1:18) or THC (5,
10, 25 or 50 mg/kg) (one injection per day for 4 days) and peritoneal
macrophages harvested 5 days later. Migration to Acanthamoeba culbertsoni
conditioned medium (AcCM; 36μg) was assessed. Results are presented as
mean ± SD. *p<0.05.
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Figure 26– CP55940 Inhibits Peritoneal Macrophage Chemotaxis to
Acanthamoeba Conditioned Medium. Peritoneal macrophages were treated
with CP55940 (CP) (10-6- 10-12 M) for 3h then assessed for migration to 36
μg Acanthamoeba (JH1) conditioned medium (JH1CM) for 1h. Results are
presented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. VEH- vehicle
(0.01% ethanol).
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the highly selective CB2 ligand O-2137 resulted in a profound and significant
concentration-related inhibition in the chemotactic response to Acanthamoeba (JH1)
conditioned medium (JH1CM; 36 μg) (Fig. 27). For drug concentrations of 10-6M – 108

M, a greater than 50% inhibition, as compared to vehicle control, was observed. In

contrast, the CB1 specific ligand ACEA (10-6M – 10-12M) had no inhibitory effect on the
peritoneal macrophage chemotactic response to Acanthamoeba (JH1) conditioned
medium (JH1CM; 36 μg) (Fig. 28).

CB2-specific Antagonist SR144528 (SR2) Reverses the Inhibitory Effect of CP55940 on
the Murine Peritoneal Macrophage Chemotactic Response to Amoebic Conditioned
Medium
Cannabinoid receptor agonist-antagonist experiments were performed to further
confirm the previous data indicating that activation of the CB2 with a cannabinoid
receptor selective ligand exerted a major inhibitory effect on the chemotactic response to
amoebic conditioned medium. For these experiments, the CB2 antagonist SR144528
(SR2) was used at a concentration of 10-6M. Treatment of (B6C3)F1 murine peritoneal
macrophages with the CB2-specific antagonist SR2 alone had no significant effect on the
B

chemotactic response to Acanthamoeba (JH1) conditioned medium (JH1CM; 54 μg), as
there was no significant difference in migration to JH1CM by SR2- or vehicle-treated
cells (Fig. 29). At equimolar concentrations (i.e., 10-6M) of antagonist and agonist,
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Figure 27 – The CB2 Selective Agonist O-2137 Inhibits Peritoneal Macrophage
Chemotaxis to Acanthamoeba Conditioned Medium. Peritoneal macrophages
were treated with O-2137 (10-6- 10-12 M) for 3h then assessed for migration to 36
μg Acanthamoeba (JH1) conditioned medium (JH1CM) for 1h. Results are
presented as mean ± SD. *p<0.05, **p<0.01. VEH- vehicle (0.01% ethanol).
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Figure 28 – The CB1 Selective Agonist ACEA Has No Effect on Peritoneal
Macrophage Migration to Acanthamoeba Conditioned Medium. Peritoneal
macrophages were treated with ACEA (10-6- 10-12 M) for 3h then assessed
for migration to 36 μg Acanthamoeba (JH1) conditioned medium (JH1CM)
for 1h. Results are presented as mean ± SD. VEH- vehicle (0.01% ethanol).
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Figure 29- Effect of Cannabinoid Receptor Antagonist on Chemotaxis to
Acanthamoeba Conditioned Medium. The CP55940 (CP)-mediated inhibition of
chemotaxis was reversed by the CB2 antagonist (SR2) SR144528 (10-6 M).
Macrophages were treated (30 min) with antagonist prior to treatment (3h) with
cannabinoid and assessed for migration to 54 μg Acanthamoeba (JH1) conditioned
medium (JH1CM)(1h). Results are presented as the mean ± SD. For cannabinoidtreated cells exposed to amoeba conditioned medium placed only in the bottom
chamber, SD was compared with that of vehicle-treated macrophages exposed to
conditioned medium in the bottom chamber. For cannabinoid-treated cells exposed
to conditioned medium placed in both chambers (shaded bars), SD was compared
with that of vehicle (VEH)-treated macrophages exposed to conditioned medium in
both chambers. ***p<0.001.
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CP55940 inhibited macrophage migration to JH1CM. Additionally, referencing Fig. 26,
CP55940-mediated inhibition of migration extended through concentrations as low as 10M, with greater than 50% inhibition observed through 10-10M. However, the inhibitory

12

effect of the agonist began to be reversed by SR2 in cells treated with 10-10M CP55940
(approximately 25% inhibition compared to 50%) and was totally reversed in cells treated
with 10-11 and 10-12 M CP55940.

THC Alters Functional Morphology of Murine Peritoneal Macrophages Undergoing
Chemotaxis to Amoebic Conditioned Medium
Transwell chemotaxis assays revealed that THC inhibits peritoneal macrophage
migration to Acanthamoeba conditioned medium. Similar to results seen of macrophages
migrating to RANTES, scanning electron microscopy analysis of the transwell
membranes demonstrated that cells treated with THC were impaired in their ability to
migrate through the pores into the bottom chamber containing the chemoattractant.
Vehicle-treated (0.01% Ethanol) peritoneal macrophages exposed to amoeba conditioned
medium exhibited characteristics indicative of cell migration including lobose cellular
extensions (Fig. 30). Additionally, numerous vehicle-treated macrophages were found in
or near the membrane pores with pseudopodia extending toward the pore (Fig. 30). In
contrast, peritoneal macrophages treated with THC were rounded in appearance, with the
absence of cellular extensions. Few THC-treated macrophages were observed in filter
pores and those cells that were proximal did not appear to be moving toward the pore.
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Figure 30– THC Alters the Morphology of Peritoneal Macrophages Migrating to
Acanthamoeba Conditioned Medium. Scanning electron microscopy of
transwell inserts of peritoneal macrophages treated with Vehicle (0.01%
Ethanol) or THC (10-6 M) (3h) migrating towards Acanthamoeba conditioned
medium (top row- Acanthamoeba JH1 conditioned medium (JH1CM), bottom
row- Acanthamoeba culbertsoni conditioned medium). Note the cellular
projections of the vehicle-treated macrophages migrating to amoebic conditioned
medium, whereas the cells treated with THC are rounded in appearance and do
not appear to be migrating toward the pores. Scale bars top row left to right 1, 1,
and 10 μm; bottom row both 10 μm.
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Treatment with THC and CP55940 Inhibits Rat Primary Microglial Migration to Amoeba
Conditioned Medium
As one of the primary sites of Acanthamoeba infection occurs in the CNS, it was
important to assess the effect of cannabinoids on migration of primary microglial cells to
amoebic conditioned medium. Treatment of primary neonatal rat microglia with THC
(10-6 -10-8 M) resulted in significant inhibition of migration to Acanthamoeba culbertsoni
conditioned medium (AcCM; 54μg) (Fig. 31). Replicate experiments using CP55940
also resulted in significant concentration-related inhibition of microglial migration to
Acanthamoeba culbertsoni conditioned medium (AcCM; 54μg) (Fig. 31). Similar
experiments assessing the effect of THC or CP55940 (10-6 M) on microglial migration to
Acanthamoeba (JH1) conditioned medium also revealed cannabinoid-mediated inhibition
(data not shown).

The CB2-selective Ligand O-2137 Inhibits Rat Primary Microglial Migration to Amoebic
Conditioned Medium
The inhibitory effect of THC and CP55940 on the migratory response of primary
microglia to amoebic conditioned medium implicated a role for a cannabinoid receptor.
Cannabinoid receptor selective agonists therefore were employed to determine the
cannabinoid receptor associated with this inhibitory effect. Treatment with O-2137, a
highly selective CB2 ligand resulted in significant inhibition of microglial migration to
Acanthamoeba (JH1) conditioned medium (JH1CM; 72 μg) conditioned medium
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Figure 31- THC and CP55940 Inhibit Chemotaxis of Microglia to
Acanthamoeba Conditioned Medium. Purified rat microglia were treated for 3 h
with cannabinoid or vehicle (VEH) (0.01% ethanol) and assessed (2h) for
migration to Acanthamoeba culbertsoni conditioned medium (AcCM; 54 μg).
Results are presented as the mean ± SD. *p<0.05, **p<0.01, ***p<0.001.
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and Acanthamoeba culbertsoni conditioned medium (AcCM; 54 μg) (Figures 32 and 33,
respectively). In contrast, treatment with the CB1 selective ligand had no effect on
microglial migration to Acanthamoeba (JH1) conditioned medium (JH1CM; 54 μg)
conditioned medium and Acanthamoeba culbertsoni conditioned medium (AcCM; 54 μg)
(Figures 32 and 33, respectively).

The CB2-specific Antagonist SR144528 Reverses the Inhibitory Effect of CP55940 on Rat
Primary Microglial Migration to Amoebic Conditioned Medium
To confirm the cannabinoid receptor associated with the inhibitory effect on
microglial migration, cannabinioid receptor agonist-antagonist experiments were
performed. For these experiments, the CB2 antagonist SR144528 (SR2) was used at a
concentration of 10-6M. Treatment of primary rat microglia with the CB2-specific
antagonist SR2 alone had no effect on the chemotactic response to Acanthamoeba
culbertsoni conditioned medium (AcCM; 54 μg), as the number of SR2-treated cells
migrating to AcCM was equivalent to the number vehicle-treated cells migrating to
AcCM (Fig. 34). CP55940 treatment alone (10-6 and 10-8M) significantly inhibited
microglial migration to AcCM. At equimolar concentrations (i.e., 10-6M) of antagonist
and agonist, CP55940 inhibited macrophage migration to AcCM. However at lower
concentrations of agonist (i.e. 10-8M), SR2 reversed CP55940-mediated inhibition.
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Figure 32- The CB2 Agonist O-2137 Inhibits Microglial Migration to Acanthamoeba
Conditioned Medium, but not the CB1 Agonist ACEA. Microglia were treated (3h) with
cannabinoid or vehicle (VEH) (0.01% ethanol) and assessed for migration to
Acanthamoeba (JH1) conditioned medium (2h) (JH1CM; 54 μg). Results are presented
as the mean ± SD. *p<0.05.
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Figure 33-The CB2 Agonist O-2137 Inhibits Microglial Migration to
Acanthamoeba Conditioned Medium, but not the CB1 Agonist ACEA.
Microglia were treated (3h) with cannabinoid (10-6M) or vehicle (VEH) (0.01%
ethanol) and assessed for migration to Acanthamoeba culbertsoni conditioned
medium (2h) (AcCM; 54 μg). Results are presented as the mean ± SD. *p<0.05.
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Figure 34 – The CB2 Antagonist Reverses CP55940-mediated Inhibition of
Primary Microglial Migration to Acanthamoeba Conditioned Medium. Primary
rat microglial cells were pretreated (30 min) with CB2 antagonist SR2 (10-6 M)
followed by treatment with 10-6- 10-8M CP55940 (CP) (3h). Migration to 54 μg A.
culbertsoni conditioned medium (AcCM) was assessed (2h). Results are presented
as the mean ± SD. Cannabinoid (CP55940, SR2, and CP55940+SR2) treated
groups were compared with vehicle (VEH)-treated microglia exposed to
conditioned medium in the bottom chamber. *p<0.05, **p<0.01. Further
statistical analysis using Bonferroni’s t-test compared groups treated with
CP55940 (10-6 M) or CP55940+SR2 (10-6 M) to SR2 (10-6 M). ††† p <0.001.
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Bonferroni’s test was performed for comparisons between treatment groups and further
confirmed a significant difference in migration to amoebic conditioned medium between
microglia treated with CP55940 (10-8M) and those treated with CP55940 (10-8M) and
SR2 (10-6M).
These experiments were complemented with those using the CB1 antagonist
SR141716A (SR1). For these experiments, CB1 antagonist SR141716A (SR1) was used
at a concentration of 10-6M. Treatment of primary rat microglia with the CB1-specific
antagonist SR1 alone had no effect on the chemotactic response to Acanthamoeba
culbertsoni conditioned medium (AcCM; 54 μg), as the number of SR1-treated cells
migrating to AcCM was equivalent to the number of vehicle-treated cells migrating to
AcCM (Fig. 35). As observed in the previous experiment using SR2 (Fig. 34), CP55940
treatment alone (10-6 and 10-8M) significantly inhibited microglial migration to AcCM.
At equimolar concentrations (i.e., 10-6M) of antagonist and agonist, CP55940 inhibited
macrophage migration to AcCM. However, treatment with the CB1 antagonist SR1 was
unable to block the inhibitory effect of CP55940.

Discussion
THC, the major psychoactive component in marijuana, has been shown to alter
the activities of macrophages and macrophage-like cells, including phagocytosis
(Friedman et al., 1986; Lopez-Cepero et al., 1986; Tang et al., 1992; Ehrhart et al.,
2005), antigen processing (McCoy et al., 1995; McCoy et al., 1999), and production of
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Figure 35– Pretreatment with the CB1 antagonist SR1 Does Not Alter CP55940Mediated Inhibition of Primary Microglial Migration to Acanthamoeba
conditioned medium. Primary microglia were pretreated with SR1 (30 min)
followed by treatment with CP55940 (CP) (3h). Migration to 54 μg A. culbertsoni
conditioned medium (AcCM) was assessed (2h). Results are presented as the
mean ± SD. Cannabinoid (CP55940, SR1, and CP55940+SR1) treated groups
were compared with vehicle (VEH)-treated microglia exposed to conditioned
medium in the bottom chamber. *p<0.05, **p<0.01, ***p<0.001. Further
statistical analysis using Bonferroni’s t-test compared groups treated with
CP55940 (10-6 M) or CP55940+SR1 (10-6 M) to SR1 (10-6 M). ††† p <0.001 and
†† p 0.002.
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chemokines and cytokines (Watzl et al., 1991; Zheng et al., 1992; Puffenbarger et al.,
2000). Recent studies indicate that this exogenous cannabinoid, as well as other
cannabinoids, also affects the migratory activities of macrophages. Stefano et al. (1998)
reported that acute exposure to the endogenous cannabinoid (endocannabinoid)
anandamide resulted in transformation of macrophages from an amoeboid and motile
state to that of a rounded and non-motile conformation. These investigators proposed
that the transforming events were linked to the CB1 receptor since the CB1-specific
B

antagonist SR141716A blocked the transformation. Sacerdote et al. (2000) demonstrated
that in vivo and in vitro treatment of rat peritoneal macrophages with CP55940, a high
efficacy agonist at both CB1 and CB2 receptors, resulted in decreased migration in vitro
to the peptide formal-methionyl-leucine-phenylalanine (fMLP). It was indicated that,
while both the CB1 and CB2 receptors appeared to be involved in this process, the
cannabinoid-mediated effect was linked primarily to the CB2. The chemotactic response
of murine macrophages to fMLP also has been shown to be decreased by cannabidiol
(Sacerdote et al., 2005), a cannabinoid that binds weakly to CB2. The CB2 antagonist
SR144528 prevented this decrease, suggesting a functional linkage to this receptor.
On the other hand, Walter et al. (2003) found that the endocannabinoid 2arachidonylglycerol (2-AG) triggered migration of microglia, macrophages that are
resident in the brain, and that the CB2 was involved in this effect. Additionally, these
investigators and others (Jorda et al., 2002; Kishimoto et al., 2005) have demonstrated
that THC did not induce a migratory cellular response in natural killer cells or cells of
myeloid origin and, further, inhibited migration of these cell types to 2-AG. Collectively,
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these studies suggest that exogenous cannabinoids exert inhibitory effects on macrophage
migration while endocannabinoids elicit an opposite effect.
Consistent with these observations, in the present study we demonstrated that
THC inhibits the chemotactic or directed migratory response of murine peritoneal
macrophages to RANTES, a chemokine that can signal through the chemokine receptors
CCR1 and CCR5. This effect was exerted on peritoneal macrophages from mice
administered THC in vivo or on peritoneal macrophages that were exposed directly to
THC in vitro. In the latter context, the inhibition occurred over a wide concentration
range (i.e., 10-6 M – 10-12 M). These results are consistent with THC as having a direct
effect on macrophages which results in inhibition of chemotaxis. Indeed, scanning
electron microscopic analysis revealed dramatic alterations in cellular morphology
following treatment with THC, indicating that these cells had reduced migratory
responsiveness. Whereas vehicle-treated cells migrating to RANTES displayed
morphological characteristics of migration including membrane ruffling and numerous
cellular projections extending toward or into membrane pores, the cells treated with THC
were rounded and appeared to be non-motile.
The results obtained with THC were replicated using the high efficacy CB1/CB2
agonist CP55940. Treatment of murine macrophages in vitro with CP55940 resulted in
inhibition of chemotaxis to RANTES over the same concentration range (i.e., 10-6 M –
10-12 M) of THC. In order to establish whether the cannabinoid-mediated inhibition was
linked to a cannabinoid receptor, a series of experiments was performed in which
cannabinoid receptor-selective agonists as well as cannabinoid receptor-specific
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antagonists were used. Treatment of macrophages in vitro with O-2137, a compound that
exhibits high selectivity for the CB2, resulted in a robust inhibition of macrophage
chemotaxis. In contrast, the CB1 selective compound ACEA had a minimal effect. In
addition, the CB2 antagonist SR144528 blocked CP55940-mediated inhibition of
macrophage chemotaxis while the CB1 antagonist SR141716A had a minimal effect.
B

Finally, THC was not able to inhibit the chemotactic response to RANTES of peritoneal
macrophages obtained from CB2 knockout mice. Collectively, the results of experiments
in which a pharmacological approach was complemented with that using macrophages
from CB2 null (i.e., CB2 -/-) mice support the proposition that the CB2 is linked
B

functionally to the THC-mediated inhibition of chemotaxis to RANTES.
RANTES, for which the current International Union of Pharmacology
nomenclature is CCL5 (Murphy, 2002), is one of many chemotactic cytokines that direct
the migration of leukocytes to sites of infection and inflammation. In this capacity, these
small molecular weight proteins constitute a critical component of innate immune
defenses. Four subfamilies of chemokines have been identified based on the relative
position of their N terminal cysteine residues. All chemokines bind specific receptors
that have seven transmembrane domains and are coupled to heterotrimeric Gi proteins, a
feature that is shared with cannabinoid agonists. However, binding within a chemokine
subfamily is somewhat promiscuous. In addition, multiple chemokine receptor types have
been identified on individual immune cells and their expression may vary in relation to
cell differentiation and activation. These characteristics confer multiple levels of
regulation and exquisitely sensitive responses to the chemokine/chemokine receptor
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system. RANTES, for example, can bind CCR1, CCR3, and CCR5, receptors that have
specialized roles in leukocyte trafficking (Murdoch and Finn, 2000; Murphy, 2002;
Charo et al., 2006). Monocytes have been reported to express a variety of chemokine
receptors, particularly CCR1, CCR2, and CCR5 (Mantovani et al., 2004). It has been
demonstrated also that differentiation of monocytes into tissue macrophages is associated
with the upregulation of CCR1 and CCR5 and loss of CCR2 expression (Mantovani et
al., 2004). In the present study, we examined thioglycollate-elicited peritoneal
macrophages from (B6C3)F1 and C57BL/6 mice for their CC chemokine receptor
expression profile. These cells were shown to express CCR1 and CCR5, receptors that
can bind RANTES. Thus, in the context of our experimental paradigm it is possible that
RANTES acted through one or both receptors to induce chemotactic activity. In turn,
THC may have affected the functionality of one or both chemokine receptors. Regardless
of which of the chemokine receptors found on macrophages is functionally relevant in
RANTES-mediated signaling, the results of this study suggest that cannabinoid activation
of the CB2 can result in deactivation of other members of the G protein-coupled family
such as chemokine receptors. Further studies utilizing chemokine receptor-specific
antagonists should serve to identify the CC receptor type that is linked to RANTESmediated chemotactic activity that is targeted by cannabinoids.
The mode by which THC and other analogs that signal through cannabinoid
receptors to deactivate CCR1 and/or CCR5 chemokine receptor migratory responsiveness
to RANTES remains to be defined. THC and other cannabinoids, as highly lipophilic
molecules, can perturb cellular membranes (Martin, 1986; Makriyannis et al., 1990;
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Cabral and Staab, 2005). Such perturbation could alter conformational strictures
requisite for ligand-receptor interaction, disrupt receptor-G protein complexes, and
disturb intracellular membranous compartments that are linked to biochemical events in
the cascade of signal transduction. However, as suggested by the present study,
cannabinoids also may trans-deactivate chemokine receptors and affect their ability to
elicit a signal transductional cascade that culminates in the chemotactic migratory
response. Indeed, it has been reported that members of the G protein coupled receptor
superfamily can associate with each other, forming homodimers and heterodimers that
results in alteration in the functionality of one of the involved receptors (Rios et al.,
2001). Opioid receptors, for example, have been reported to interact with chemokine
receptors to alter their function. Grimm et al. (1998) indicated that this interaction
resulted in trans-deactivation of chemokine receptors and that it occurred through a
process of receptor-mediated heterologous desensitization. Desensitization is the
functional result of receptor phosphorylation by G protein coupled receptor kinases
(GRKs) or other second messenager kinases (i.e., protein kinase C), which prevents
further coupling to G proteins. Following arrestin binding, the phosphorylated receptor
undergoes internalization and recycling.
In their studies, Grimm et al. (1998) demonstrated that met-enkephalin and
morphine inhibited interleukin (IL)-8-induced chemotaxis of human neutrophils and
macrophage inflammatory protein (MIP)-1α, RANTES, and monocyte chemoattractant
protein (MCP)-1-mediated chemotaxis of human monocytes. This inhibition was
indicated as mediated by δ- and μ-opioid receptors, the activation of which led to
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phosphorylation of the chemokine receptors CXCR1 and CXCR2 resulting in
heterologous desensitization. Rogers et al. (2000) reported that activation of opioid and
chemokine receptors could lead to reciprocal down-regulation of leukocyte migratory
activities. These observations have been extended using a number of experimental
paradigms (Szabo and Rogers, 2001; Szabo et al., 2001; Szabo et al., 2002; Suzuki et al.,
2003; Zhang et al., 2003). Indeed, it has been proposed that cross-desensitization of
chemokine receptors by opioids represents a significant element in opioid-mediated
immunosuppression (Zhang et al., 2003). The process of heterologous desensitization
may also apply to cannabinoid receptors, and these studies may serve to elucidate, in part,
the mechanism of cannabinoid-mediated immunosuppression. Ghosh et al. (2006)
reported that the CB1/CB2 agonist CP55940, as well as the CB2-selective agonist JW-015,
B

caused significant inhibition of chemokine CXCL12-induced chemotaxis of CD4+ and
CD8+ T lymphocytes. These investigators also found that these cannabinoids inhibited
CXCL12 induced chemotaxis and transendothelial migration of Jurkat T cells. Rios et al.
(2006) reported recently that the μ opioid receptor also interacts with the CB1 to affect a
B

reciprocal inhibition of receptor signaling and receptor-induced neuritogenesis.
In the present study, we propose that heterologous desensitization may articulate a
mode of action by which cannabinoids mediate inhibition of the murine peritoneal
macrophage chemotactic response to RANTES. Thus, in order to obtain initial insight as
to the process by which THC and other cannabinoids cross-deactivate this macrophage
activity, a multiprobe RNase protection assay was performed to assess for levels of CC
chemokine receptor mRNAs. THC over a concentration range of 10-6M to 10-12M had no
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effect on macrophage mRNA levels of CCR1 and CCR5. Likewise, treatment with other
cannabinoid receptor agonists and antagonists including CP55940, SR1 and SR2 (10-6M)
had no effect on CCR1 or CCR5 mRNA as assessed by multiprobe RNase protection
assay. These results are consistent with THC-mediated inhibition of the chemotactic
process as occurring at a level of regulation other than gene expression of the cognate
receptors at the mRNA level. Immunoprecipitation experiments followed by Western
blot analysis using a primary antibody specific for phosphorylated serine residues were
performed to assess for effects of cannabinoids on protein expression and
phosphorylation of CCR5, which notably undergoes serine phosphorylation. Stimulation
with the cognate ligand RANTES induced CCR5 phosphorylation as compared to cells
treated with vehicle. Further, treatment with CP55940 (10-6M) resulted in the induction
of CCR5 phosphorylation. The level of CCR5 phosphorylation induced by CP55940 was
less than the level of phosphorylation following stimulation with RANTES, results which
are consistent with reports by Chen et al. (2004) who demonstrated that treatment with μopioid receptor agonist DAMGO induced CCR5 phosphorylation but to a lesser extent
than RANTES.
Cannabinoids can also affect migration to chemotactic molecules other than
chemokines including bioactive lipids such as 2-AG. 2-Arachidonoylglycerol (2-AG) is
an endogenous cannabinoid (endocannabinoid) that is a native ligand to cannabinoid
receptors in the CNS and in the periphery. Formation of 2-AG occurs rapidly through the
cleavage of membrane phospholipids by phospholipases and diacylglycerol lipase. It is
produced by numerous cell types under a wide variety of stimulatory conditions including
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LPS stimulation of rat macrophages (DiMarzo et al., 1999), ATP stimulation of mouse
microglia (Witting et al., 2004), cholera toxin-treated mouse small intestine (Izzo et al.,
2003), macrophage colony stimulating factor treated rat microglia (Carrier et al., 2004),
and mouse brain following traumatic brain injury (Panikashvili et al., 2001). Indeed, it
has been proposed that 2-AG plays a physiological role in the regulation of
neurotransmitter release (Sugiura and Waku, 2000), the cardiovascular system (reviewed
in Sugiura et al., 2006), and the proliferation and invasion of certain types of cancer cells
(reviewed in Sugiura et al., 2006). It seems very likely, therefore, that 2-AG plays an
essential role in the regulation of a variety of biological systems.
Accumulating evidence also suggests that 2-AG is involved in
immunomodulation. Kishimoto et al. (2004) reported that 2-AG induced production of
interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1), and that this
effect was linked to CB2. Further, addition of LPS to 2-AG synergistically augmented
IL-8 and MCP-1 production. 2-AG has also been shown to modulate other activities
associated with the inflammatory response inducing changes in cellular morphology
through rapid actin rearrangement (Gokoh et al., 2005), enhancing cellular adhesion
(Gokoh et al., 2005), and stimulating cell migration. Walter et al. (2003) demonstrated
that 2-AG induced migration in microglia, and that this migration was linked to activation
of CB2. Further, localization of CB2 to the leading edge of lamellipodia implicated a role
for CB2 in migration (Walter et al., 2003). Additional studies (Jorda et al., 2002;
Kishimoto et al., 2005) demonstrated that 2-AG induces migration in multiple immune
cell types and that treatment with THC can inhibit this migration. It has recently been
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proposed by Cabral et al. (2007) that cannabinoids alter macrophage migration through
activation of CB2, with endocannabinoids such as 2-AG exerting a stimulatory effect and
exogenous cannabinoids eliciting an opposite, inhibitory effect. Endogenous
cannabinoids such as 2-AG, signaling through CB2, may stimulate or support an
inflammatory response through the increase in cell adhesion and migration, the activation
of mitogen-activated protein kinase (MAP kinase), induction of [Ca2+] release, and
upregulation of chemokine production whereas other CB2 ligands may block these
effects. This block could be the result of competition for receptor binding involving
limiting factors such as ligand accessibility (generation and short half-life of endogenous
ligands) or ligand affinity.
As a critical component in innate immunity, macrophages play a key role in
recognition and clearance of bacterial, protozoan, and viral pathogens. Integral to this
recognition process are a host of cellular receptors. For example, pattern recognition
receptors recognize pathogen associated molecular pattern (PAMPs), which include
bacterial carbohydrate moieties like mannose or LPS; bacterial, viral, protozoan RNA or
DNA; and viral glycoproteins. Host cells also express a class of G-protein coupled
receptors designated Protease-activated receptors (PARs1-4) that can be activated by
immune cell-derived or microorganism-derived serine proteases (Steinhoff et al., 2005;
Traynelis and Trejo, 2007). PAR1and PAR2 can coupled to Gαq, Gαi, Gα12/13, and Gβγ
and induce multiple signal transduction cascades. PAR1/2 activation induces protein
kinase C (PKC) and MAP kinase activation, Rho/Rac signaling, mobilization of
intracellular calcium [Ca2+] through activation of phospholipase C (PLC), and activation
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of receptor tyrosine kinases (RTKs) (Traynelis and Trejo, 2007). Activation of these
signaling networks results in alterations in cell shape, adhesion, secretion of
inflammatory mediators, and motility. PAR1 is expressed in a variety of cells including
platelets, endothelial cells, CD8+ T cells, monocytes, migroglia, astrocytes, neurons,
mast cells, and certain tumor cells (reviewed in Steinhoff et al., 2005). PAR2 is
expressed by immune cells including dendritic cells, eosinophils, macrophages, and
neutrophils (Miike et al., 2001; Colognato et al., 2003; Howells et al., 1997; Moormann
et al., 2006). Serine proteases and PARs have been implicated in immune and
inflammatory regulation; however, the majority of the data to date is limited to PAR
modulation of cell adhesion molecules, chemokine/cytokine production, and cell
migration. Colotta et al. (1994) reported that thrombin, acting through PAR1, induced
expression of MCP-1 by human peripheral blood mononuclear cells (PBMC).
Additionally, treatment of endothelial cells with thrombin, which signals through PAR1,
induced IL-8, E-selectin (Kaplanski et al., 1997), intercellular adhesion molecule-1
(ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) expression (Kaplanski et
al., 1998). PAR1 activation with thrombin has also been shown to induce human
neutrophil chemotaxis (Mariano-Oliveira et al., 2007). Morris et al. (2006) demonstrated
that PAR2 plays a critical role in breast cancer cell migration and invasion.
Many bacteria and amebae that are pathogenic in humans produce serine
proteases. It is reasonable, therefore, to postulate that these pathogen-derived proteases
may trigger specific immune or inflammatory responses through direct interaction with
host cell PARs. Amebae of the genus Acanthamoeba have been shown to secrete
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multiple serine, cysteine, and matrix metalloproteases that have been implicated in the
virulence of the pathogen (Marciano-Cabral and Cabral, 2003). These proteases are
thought to play a role in tissue destruction and pathogen invasion, and are capable of
degrading host IgA and IgG, multiple extracellular matrix components including types I
and III collagen, and serum proteins hemoglobin and fibrinogen (Kong et al., 2000; Mitro
et al., 1994; Cho et al., 2000; and Sissons et al., 2006). In the present study we
demonstrated that peritoneal macrophages migrate towards media conditioned with two
strains of Acanthamoeba (Acanthamoeba culbertsoni and Acanthamoeba JH1, which
contains intracellular gram negative bacteria). Acanthamoeba conditioned medium has
been shown to contain a variety of proteases including serine and metalloproteases
(Sissons et al., 2006). The chemoattractants in the amoebic conditioned medium seem to
be directly produced by the amoeba, as there was no major difference in cell migration to
the conditioned medium derived from culture with Acathamoeba culbertsoni or from
medium cultured with Acanthamoeba JH1 harboring intracellular bacteria. We also
found that THC inhibits the chemotactic response of murine peritoneal macrophages to
Acanthamoeba conditioned medium. This inhibitory effect was exerted on peritoneal
macrophages from mice administered THC in vivo or on peritoneal macrophages that
were exposed directly to THC in vitro. Scanning electron microscopic analysis revealed
dramatic alterations in macrophage morphology following treatment with THC,
indicating that these cells had reduced migratory responsiveness similar to previous
results obtained using RANTES as the chemoattractant. Vehicle-treated cells migrating
to Acanthamoeba conditioned medium displayed morphological characteristics of
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migration including membrane ruffling and numerous cellular projections extending
toward or into membrane pores; however, as demonstrated in previous studies the
macrophages treated with THC appeared to be rounded and non-motile.
We then employed a strategy similar to the one previously utilized in the
RANTES studies to determine whether a cannabinoid receptor was involved in inhibition
of macrophage migration to amoebic conditioned medium. Experiments were repeated
using the high efficacy CB1/CB2 agonist CP55940. Treatment of peritoneal
macrophages in vitro with CP55940 resulted in significant inhibition of migration to
Acanthamoeba conditioned medium. In addition, we performed experiments using
compounds exhibiting selective high affinity binding to the CB1 or the CB2 prior to
assessment of the chemotactic response to amoebic conditioned medium (ACEA and O2137, respectively). Treatment of macrophages with the selective CB2 ligand O-2137
resulted in significant concentration-related inhibition in the migration to Acanthamoeba
conditioned medium. The CB1 specific ligand ACEA had no effect on peritoneal
macrophage migration to Acanthamoeba conditioned medium. Further experiments
employing cannabinoid receptor antagonists used in concert with CP55940 were
performed. The CB2 antagonist SR144528 blocked CP55940-mediated inhibition of
macrophage migration to amoebic conditioned medium while the CB1 antagonist
SR141716A had a minimal effect. Together, these results imply that CB2 is linked to
B

cannabinoid-mediated inhibition of macrophage migration to Acanthamoeba conditioned
medium.
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For many years the brain was believed to be an immune privileged site, however
accumulating evidence suggests that, like the periphery, the CNS is under constant
immune surveillance. Microglia are a resident population of cells in the CNS that are
morphologically, phenotypically, and functionally related to macrophages (Aloisi, 2001;
Gehrmann et al., 1995). Upon activation by inflammatory or infectious stimuli, these
cells undergo proliferation and functional maturation with alterations in receptor
expression and the production of inflammatory mediators like cytokines, chemokines,
and reactive oxygen species (Aloisi, 2001). Dysregulation of this response, or chronic
activation, has been implicated in neuropathological diseases like Multipe Sclerosis
(MS), Alzheimer’s disease (AD), Parkinson’s disease, and Acquired Immune Deficiency
(AIDS) dementia (reviewed in Bajetto et al., 2002).
A signature activity of activated microglia is migration to sites of inflammation or
infection. Using a mouse model of Acanthamoeba infection in the CNS, Cabral et al.
(2007) demonstrated the involvement of macrophage-like (microglia) cells in the
formation of immune cell granulomas surrounding Acanthamoeba culbertsoni cysts.
Granulomas are believed to sequester pathogens preventing further dissemination. Mice
administered THC in vivo experienced higher rates of mortality following infection with
the amoebae which may be due, in part, to the observed inability to form granulomas.
We postulated that the absence of granulomas following THC might be the consequence
of a cannabinoid-mediated inhibition of microglial migration. In the final part of the
study, we utilized an in vitro migration system with primary rat microglial cells and
Acanthamoeba conditioned medium to model an in vivo infection and assess the effect of
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THC on microglial migration. Treatment of primary neonatal rat microglia with THC or
CP55940 (10-6-10-8M) resulted in significant concentration-related inhibition of
microglial migration to Acanthamoeba conditioned medium.
Carlisle and Cabral (2002) reported that microglia constitutively express very low
levels of CB1, whereas CB2 is expressed differentially in relation to cell activation state.
B

CB2 is expressed at high levels in microglia when they are in responsive or primed states.
These activation states are characterized by differential gene expression and certain
functional activities. In responsive and primed states macrophages and microglia are
capable of chemotaxis, phagocytosis, and antigen presentation, activities that correlate
with early inflammatory responses. We performed migration assays using compounds
exhibiting selective binding to the CB1 or the CB2 prior to assessment of the chemotactic
response to amoebic conditioned medium. Treatment of macrophages with the CB2
ligand O-2137 resulted in significant concentration-related inhibition in the migration to
Acanthamoeba conditioned medium; however, the CB1 specific ligand ACEA had no
effect on microglial migration to Acanthamoeba conditioned medium. Further
experiments using CB1 and CB2 specific antagonists in combination with CP55940 were
also performed. Treatment with the CB2 antagonist SR144528 blocked CP55940mediated inhibition of microglial migration to amoebic conditioned medium while the
CB1 antagonist SR141716A had no effect. These data suggest cannabinoid-mediated
inhibition of microglial migration to Acanthamoeba conditioned medium is linked to the
CB2 cannabinoid receptor, which is consistent with the known cannabinoid receptor
expression profile of microglia, as well as the results from previous models used in our
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studies. Furthermore, since migration can be elicited by protease activation of PARs on
microglia, it is possible that THC-mediated inhibition of the chemotactic response to
amoebic conditioned medium may be due to CB2 “cross-talk” with PARs. Studies to
establish such a functional linkage should serve to clarify whether the CB2 receptor can
“cross-communicate” with a diverse array of G-protein coupled receptors so as to
modulate responsiveness by macrophages and macrophage-like cells.
In summary, we have demonstrated that THC and other exogenous cannabinoids
that activate the CB2 inhibit murine peritoneal macrophage chemotaxis to
RANTES/CCL5. This inhibitory effect was linked functionally to the CB2 receptor.
B

Furthermore, since this chemokine serves as a ligand for CCR1 and CCR5, these results
suggest that activation of the CB2 leads to trans-deactivation of these G protein-coupled
receptors of the CC chemokine subfamily that have specialized roles in leukocyte
trafficking. Thus, as has been suggested for opioid receptors, CB2 “cross-talk” with
chemokine receptors may constitute an integrative component of a network of
intercommunicating G protein-coupled receptors that regulate immune responses. In
addition, we have demonstrated that THC and other exogenous cannabinoids that activate
the CB2 inhibit murine peritoneal macrophage and rat primary microglial chemotaxis to
Acanthamoeba conditioned medium. Cannabinoids, as acting through cannabinoid
receptors, may “cross-communicate” with a diverse array of G-protein coupled receptors,
thereby affecting activation of receptors such as CCR5 and PARs. Although much more
work needs to be done to link the chemotactic response of macrophages and microglia to
amoebic conditioned medium to PAR activation and to establish whether heterologous
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desensitization is occurring between CB2 and PARs, this study provides initial insight to
the mechanism of THC-mediated immunosuppression in CNS infections with amoeba.
We also have shown that the endogenous cannabinoid, 2-AG induces migration of
peritoneal macrophages and that this effect can be inhibited by the exogenous
cannabinoid, THC. We have proposed a model in which endogenous cannabinoids
signaling through CB2 exert a positive or stimulatory effect on the inflammatory
response, whereas exogenous cannabinoids elicit an inhibitory effect. These studies
demonstrate a critical role for CB2 in immunoregulation and inflammation in the CNS
and the periphery.
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